{
    "geneDrugGroup": [
        {
            "standardDrugName": "LAROTRECTINIB",
            "showDrugName": "LAROTRECTINIB",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": "TARGETED_THERAPY",
            "target": true,
            "pubchemId": [
                46188928
            ],
            "dScore": 0.915,
            "gScore": 0.4509,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "NTRK1": "mutated"
                },
                "coherence": {
                    "NTRK1": "NTRK1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                }
            ],
            "family": [
                "tropomyosin receptor kinase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "MOAl",
                    "link": "https://moalmanac.org",
                    "name": "MOAlmanac"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "MOAlmanac"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LAROTRECTINIB",
                    "showDrugName": "LAROTRECTINIB",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LAROTRECTINIB is a drug approved by FDA that acts as an inhibitor of NTRK1",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.915,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "MOAlmanac",
                        "TTD"
                    ],
                    "family": [
                        "tropomyosin receptor kinase inhibitor(Cmap)"
                    ],
                    "alteration": [
                        {
                            "gene": "NTRK1",
                            "alteration": "rearrangement",
                            "drugSource": "MOAlmanac"
                        }
                    ],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "GEMCITABINE",
            "showDrugName": "GEMCITABINE",
            "status": "APPROVED",
            "statusDescription": "Approved for breast, lung, ovary and pancreas cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                60750
            ],
            "dScore": 0.8320000000000001,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "MSH5": "mutated",
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "MSH5": "MSH5 is mutated",
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "MSH5",
                    "entrezId": [
                        4439
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "ribonucleotide reductase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GDSC",
                    "link": "http://www.cancerrxgene.org/translation/Gene/GDSC",
                    "name": "GDSC"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST",
                "LUNG",
                "OVARY",
                "PANCREAS"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "GEMCITABINE",
                    "showDrugName": "GEMCITABINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to GEMCITABINE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8320000000000001,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "LUNG",
                        "OVARY",
                        "PANCREAS"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "ribonucleotide reductase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "GEMCITABINE",
                    "showDrugName": "GEMCITABINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to GEMCITABINE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8310000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "LUNG",
                        "OVARY",
                        "PANCREAS"
                    ],
                    "source": [
                        "GDSC"
                    ],
                    "family": [
                        "ribonucleotide reductase inhibitor(Cmap)"
                    ],
                    "alteration": [
                        {
                            "gene": "BRAF",
                            "alteration": "mutation",
                            "drugSource": "GDSC"
                        }
                    ],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "GEMCITABINE",
                    "showDrugName": "GEMCITABINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in MSH5 are associated with response to GEMCITABINE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8310000000000001,
                    "gScore": 0.2075,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "MSH5",
                            "entrezId": [
                                4439
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "LUNG",
                        "OVARY",
                        "PANCREAS"
                    ],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "ribonucleotide reductase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DOXORUBICIN",
            "showDrugName": "DOXORUBICIN",
            "status": "APPROVED",
            "statusDescription": "Approved for adrenal gland, bladder, blood, blood and lymph vessels, bone, bone marrow, breast, kidney, lung, ovary, soft tissue, stomach and thyroid cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                31703
            ],
            "dScore": 0.8320000000000001,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated",
                    "BLM": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated",
                    "BLM": "BLM (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                },
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "topoisomerase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [
                "DTC",
                "JAX-CKB"
            ],
            "cancer": [
                "ADRENAL_GLAND",
                "BLADDER",
                "BLOOD",
                "BLOOD_AND_LYMPH_VESSELS",
                "BONE",
                "BONE_MARROW",
                "BREAST",
                "KIDNEY",
                "LUNG",
                "OVARY",
                "SOFT_TISSUE",
                "STOMACH",
                "THYROID"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "DOXORUBICIN",
                    "showDrugName": "DOXORUBICIN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to DOXORUBICIN, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8320000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "ADRENAL_GLAND",
                        "BLADDER",
                        "BLOOD",
                        "BLOOD_AND_LYMPH_VESSELS",
                        "BONE",
                        "BONE_MARROW",
                        "BREAST",
                        "KIDNEY",
                        "LUNG",
                        "OVARY",
                        "SOFT_TISSUE",
                        "STOMACH",
                        "THYROID"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "topoisomerase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "DOXORUBICIN",
                    "showDrugName": "DOXORUBICIN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to DOXORUBICIN, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8320000000000001,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [
                        "ADRENAL_GLAND",
                        "BLADDER",
                        "BLOOD",
                        "BLOOD_AND_LYMPH_VESSELS",
                        "BONE",
                        "BONE_MARROW",
                        "BREAST",
                        "KIDNEY",
                        "LUNG",
                        "OVARY",
                        "SOFT_TISSUE",
                        "STOMACH",
                        "THYROID"
                    ],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "topoisomerase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "DOXORUBICIN",
                    "showDrugName": "DOXORUBICIN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to DOXORUBICIN, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8320000000000001,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [
                        "ADRENAL_GLAND",
                        "BLADDER",
                        "BLOOD",
                        "BLOOD_AND_LYMPH_VESSELS",
                        "BONE",
                        "BONE_MARROW",
                        "BREAST",
                        "KIDNEY",
                        "LUNG",
                        "OVARY",
                        "SOFT_TISSUE",
                        "STOMACH",
                        "THYROID"
                    ],
                    "source": [
                        "DTC",
                        "PharmGKB"
                    ],
                    "family": [
                        "topoisomerase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ALPELISIB",
            "showDrugName": "ALPELISIB",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [
                56649450
            ],
            "dScore": 0.8230000000000001,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "PI3K inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CFB",
                    "link": "http://dgidb.genome.wustl.edu/sources/ClearityFoundationBiomarkers",
                    "name": "ClearityFoundationBiomarkers"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "ClearityFoundationBiomarkers",
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ALPELISIB",
                    "showDrugName": "ALPELISIB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to ALPELISIB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8230000000000001,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "ClearityFoundationBiomarkers",
                        "JAX-CKB"
                    ],
                    "family": [
                        "PI3K inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": [
                        "PTEN deficiency is associated with reduced sensitivity to mTOR inhibition"
                    ]
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ALPELISIB",
                    "showDrugName": "ALPELISIB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to ALPELISIB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "PI3K inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "001, RAD",
            "showDrugName": "EVEROLIMUS",
            "status": "APPROVED",
            "statusDescription": "Approved for brain, breast, intestine, kidney, lung, pancreas, spinal cord and stomach cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [
                6442177
            ],
            "dScore": 0.8230000000000001,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "mTOR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CFB",
                    "link": "http://dgidb.genome.wustl.edu/sources/ClearityFoundationBiomarkers",
                    "name": "ClearityFoundationBiomarkers"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "ClearityFoundationBiomarkers",
                "JAX-CKB"
            ],
            "cancer": [
                "BRAIN",
                "BREAST",
                "INTESTINE",
                "KIDNEY",
                "LUNG",
                "PANCREAS",
                "SPINAL_CORD",
                "STOMACH"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "001, RAD",
                    "showDrugName": "EVEROLIMUS",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to EVEROLIMUS, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8230000000000001,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BRAIN",
                        "BREAST",
                        "INTESTINE",
                        "KIDNEY",
                        "LUNG",
                        "PANCREAS",
                        "SPINAL_CORD",
                        "STOMACH"
                    ],
                    "source": [
                        "ClearityFoundationBiomarkers",
                        "JAX-CKB"
                    ],
                    "family": [
                        "mTOR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "001, RAD",
                    "showDrugName": "EVEROLIMUS",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to EVEROLIMUS, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BRAIN",
                        "BREAST",
                        "INTESTINE",
                        "KIDNEY",
                        "LUNG",
                        "PANCREAS",
                        "SPINAL_CORD",
                        "STOMACH"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "mTOR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PEMBROLIZUMAB",
            "showDrugName": "PEMBROLIZUMAB",
            "status": "APPROVED",
            "statusDescription": "Approved for bladder, blood, brain, breast, colon, esophagus, head and neck, kidney, liver, lung, rectum, skin, spinal cord, stomach and uterus cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [],
            "dScore": 0.8230000000000001,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "FDA",
                    "link": "https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling",
                    "name": "FDA"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                },
                {
                    "shortName": "MOAl",
                    "link": "https://moalmanac.org",
                    "name": "MOAlmanac"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [
                "FDA",
                "JAX-CKB",
                "MOAlmanac"
            ],
            "cancer": [
                "BLADDER",
                "BLOOD",
                "BRAIN",
                "BREAST",
                "COLON",
                "ESOPHAGUS",
                "HEAD_AND_NECK",
                "KIDNEY",
                "LIVER",
                "LUNG",
                "RECTUM",
                "SKIN",
                "SPINAL_CORD",
                "STOMACH",
                "UTERUS"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PEMBROLIZUMAB",
                    "showDrugName": "PEMBROLIZUMAB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to PEMBROLIZUMAB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8230000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BLADDER",
                        "BLOOD",
                        "BRAIN",
                        "BREAST",
                        "COLON",
                        "ESOPHAGUS",
                        "HEAD_AND_NECK",
                        "KIDNEY",
                        "LIVER",
                        "LUNG",
                        "RECTUM",
                        "SKIN",
                        "SPINAL_CORD",
                        "STOMACH",
                        "UTERUS"
                    ],
                    "source": [
                        "FDA",
                        "JAX-CKB",
                        "PharmGKB"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PEMBROLIZUMAB",
                    "showDrugName": "PEMBROLIZUMAB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to PEMBROLIZUMAB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "RESISTANCE",
                    "dScore": -0.8230000000000001,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BLADDER",
                        "BLOOD",
                        "BRAIN",
                        "BREAST",
                        "COLON",
                        "ESOPHAGUS",
                        "HEAD_AND_NECK",
                        "KIDNEY",
                        "LIVER",
                        "LUNG",
                        "RECTUM",
                        "SKIN",
                        "SPINAL_CORD",
                        "STOMACH",
                        "UTERUS"
                    ],
                    "source": [
                        "JAX-CKB",
                        "MOAlmanac"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [
                        {
                            "gene": "PTEN",
                            "alteration": "copy_number; somatic_variant",
                            "drugSource": "MOAlmanac"
                        }
                    ],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "5-FLUOROURACIL",
            "showDrugName": "FLUOROURACIL",
            "status": "APPROVED",
            "statusDescription": "Approved for breast, colon, pancreas, rectum, skin and stomach cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                3385
            ],
            "dScore": 0.8220000000000001,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "thymidylate synthase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST",
                "COLON",
                "PANCREAS",
                "RECTUM",
                "SKIN",
                "STOMACH"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "5-FLUOROURACIL",
                    "showDrugName": "FLUOROURACIL",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to FLUOROURACIL, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "COLON",
                        "PANCREAS",
                        "RECTUM",
                        "SKIN",
                        "STOMACH"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "thymidylate synthase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "5-FLUOROURACIL",
                    "showDrugName": "FLUOROURACIL",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to FLUOROURACIL, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8210000000000001,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "COLON",
                        "PANCREAS",
                        "RECTUM",
                        "SKIN",
                        "STOMACH"
                    ],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "thymidylate synthase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PALBOCICLIB",
            "showDrugName": "PALBOCICLIB",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [
                5330286
            ],
            "dScore": 0.8220000000000001,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "CDK inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PALBOCICLIB",
                    "showDrugName": "PALBOCICLIB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to PALBOCICLIB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "CDK inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PALBOCICLIB",
                    "showDrugName": "PALBOCICLIB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to PALBOCICLIB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "CDK inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TRASTUZUMAB",
            "showDrugName": "TRASTUZUMAB",
            "status": "APPROVED",
            "statusDescription": "Approved for breast, esophagus and stomach cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [],
            "dScore": 0.8220000000000001,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST",
                "ESOPHAGUS",
                "STOMACH"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TRASTUZUMAB",
                    "showDrugName": "TRASTUZUMAB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to TRASTUZUMAB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "ESOPHAGUS",
                        "STOMACH"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TRASTUZUMAB",
                    "showDrugName": "TRASTUZUMAB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to TRASTUZUMAB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "ESOPHAGUS",
                        "STOMACH"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CYCLOPHOSPHAMIDE",
            "showDrugName": "CICLOPHOSPHAMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved for adrenal gland, blood, bone marrow, breast, eye and ovary cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                2907
            ],
            "dScore": 0.8220000000000001,
            "gScore": 0.4509,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated",
                    "NTRK1": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated",
                    "NTRK1": "NTRK1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                }
            ],
            "family": [
                "DNA alkylating agent(Cmap)"
            ],
            "source": [
                {
                    "shortName": "NCI",
                    "link": "https://dgidb.genome.wustl.edu/sources/NCI",
                    "name": "NCI"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [
                "NCI"
            ],
            "cancer": [
                "ADRENAL_GLAND",
                "BLOOD",
                "BONE_MARROW",
                "BREAST",
                "EYE",
                "OVARY"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CYCLOPHOSPHAMIDE",
                    "showDrugName": "CICLOPHOSPHAMIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in NTRK1 are associated with response to CICLOPHOSPHAMIDE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [
                        "ADRENAL_GLAND",
                        "BLOOD",
                        "BONE_MARROW",
                        "BREAST",
                        "EYE",
                        "OVARY"
                    ],
                    "source": [
                        "NCI"
                    ],
                    "family": [
                        "DNA alkylating agent(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CYCLOPHOSPHAMIDE",
                    "showDrugName": "CICLOPHOSPHAMIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to CICLOPHOSPHAMIDE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8210000000000001,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [
                        "ADRENAL_GLAND",
                        "BLOOD",
                        "BONE_MARROW",
                        "BREAST",
                        "EYE",
                        "OVARY"
                    ],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "DNA alkylating agent(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "METHOTREXATE",
            "showDrugName": "METHOTREXATE",
            "status": "APPROVED",
            "statusDescription": "Approved for blood, bone, breast, head and neck, lung and uterus cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                126941
            ],
            "dScore": 0.8220000000000001,
            "gScore": 0.4509,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated",
                    "NTRK1": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated",
                    "NTRK1": "NTRK1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                }
            ],
            "family": [
                "dihydrofolate reductase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "NCI",
                    "link": "https://dgidb.genome.wustl.edu/sources/NCI",
                    "name": "NCI"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [
                "NCI"
            ],
            "cancer": [
                "BLOOD",
                "BONE",
                "BREAST",
                "HEAD_AND_NECK",
                "LUNG",
                "UTERUS"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "METHOTREXATE",
                    "showDrugName": "METHOTREXATE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in NTRK1 are associated with response to METHOTREXATE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8220000000000001,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [
                        "BLOOD",
                        "BONE",
                        "BREAST",
                        "HEAD_AND_NECK",
                        "LUNG",
                        "UTERUS"
                    ],
                    "source": [
                        "NCI"
                    ],
                    "family": [
                        "dihydrofolate reductase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "METHOTREXATE",
                    "showDrugName": "METHOTREXATE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to METHOTREXATE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.8210000000000001,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [
                        "BLOOD",
                        "BONE",
                        "BREAST",
                        "HEAD_AND_NECK",
                        "LUNG",
                        "UTERUS"
                    ],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "dihydrofolate reductase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FULVESTRANT",
            "showDrugName": "FULVESTRANT",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "HORMONE_THERAPY",
            "target": false,
            "pubchemId": [
                104741
            ],
            "dScore": 0.812,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "estrogen receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "FULVESTRANT",
                    "showDrugName": "FULVESTRANT",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to FULVESTRANT, a drug approved by FDA",
                    "therapy": "HORMONE_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "estrogen receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "OLAPARIB",
            "showDrugName": "OLAPARIB",
            "status": "APPROVED",
            "statusDescription": "Approved for breast, fallopian tube, ovary, pancreas, peritoneum and prostate cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [
                23725625
            ],
            "dScore": 0.812,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "PARP inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST",
                "FALLOPIAN_TUBE",
                "OVARY",
                "PANCREAS",
                "PERITONEUM",
                "PROSTATE"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "OLAPARIB",
                    "showDrugName": "OLAPARIB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to OLAPARIB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "FALLOPIAN_TUBE",
                        "OVARY",
                        "PANCREAS",
                        "PERITONEUM",
                        "PROSTATE"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "PARP inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TALAZOPARIB",
            "showDrugName": "TALAZOPARIB",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [
                135565082
            ],
            "dScore": 0.812,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "PARP inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TALAZOPARIB",
                    "showDrugName": "TALAZOPARIB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to TALAZOPARIB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "PARP inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ATEZOLIZUMAB",
            "showDrugName": "ATEZOLIZUMAB",
            "status": "APPROVED",
            "statusDescription": "Approved for bladder, breast, liver, lung and skin cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [],
            "dScore": 0.812,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BLADDER",
                "BREAST",
                "LIVER",
                "LUNG",
                "SKIN"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ATEZOLIZUMAB",
                    "showDrugName": "ATEZOLIZUMAB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to ATEZOLIZUMAB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BLADDER",
                        "BREAST",
                        "LIVER",
                        "LUNG",
                        "SKIN"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BEVACIZUMAB",
            "showDrugName": "BEVACIZUMAB",
            "status": "APPROVED",
            "statusDescription": "Approved for brain, breast, colon, fallopian tube, kidney, liver, lung, ovary, peritoneum, rectum and uterus cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [],
            "dScore": 0.812,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BRAIN",
                "BREAST",
                "COLON",
                "FALLOPIAN_TUBE",
                "KIDNEY",
                "LIVER",
                "LUNG",
                "OVARY",
                "PERITONEUM",
                "RECTUM",
                "UTERUS"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "BEVACIZUMAB",
                    "showDrugName": "BEVACIZUMAB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to BEVACIZUMAB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BRAIN",
                        "BREAST",
                        "COLON",
                        "FALLOPIAN_TUBE",
                        "KIDNEY",
                        "LIVER",
                        "LUNG",
                        "OVARY",
                        "PERITONEUM",
                        "RECTUM",
                        "UTERUS"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LAPATINIB",
            "showDrugName": "LAPATINIB",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [
                208908
            ],
            "dScore": 0.812,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "EGFR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LAPATINIB",
                    "showDrugName": "LAPATINIB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to LAPATINIB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "EGFR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RIBOCICLIB",
            "showDrugName": "RIBOCICLIB",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [
                44631912
            ],
            "dScore": 0.812,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "CDK inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "RIBOCICLIB",
                    "showDrugName": "RIBOCICLIB",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to RIBOCICLIB, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "CDK inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TAMOXIFEN",
            "showDrugName": "TAMOXIFEN",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "HORMONE_THERAPY",
            "target": false,
            "pubchemId": [
                2733526
            ],
            "dScore": 0.812,
            "gScore": 0.4509,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "NTRK1": "mutated"
                },
                "coherence": {
                    "NTRK1": "NTRK1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                }
            ],
            "family": [
                "estrogen receptor antagonist(Cmap)",
                "selective estrogen receptor modulator (SERM)(Cmap)"
            ],
            "source": [
                {
                    "shortName": "NCI",
                    "link": "https://dgidb.genome.wustl.edu/sources/NCI",
                    "name": "NCI"
                }
            ],
            "curatedSource": [
                "NCI"
            ],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TAMOXIFEN",
                    "showDrugName": "TAMOXIFEN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in NTRK1 are associated with response to TAMOXIFEN, a drug approved by FDA",
                    "therapy": "HORMONE_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "NCI"
                    ],
                    "family": [
                        "estrogen receptor antagonist(Cmap)",
                        "selective estrogen receptor modulator (SERM)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DOCETAXEL TRIHYDRATE",
            "showDrugName": "DOCETAXEL TRIHYDRATE",
            "status": "APPROVED",
            "statusDescription": "Approved for breast, esophagus, head and neck, lung, prostate and stomach cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                148123,
                22600501,
                24721032,
                51051642,
                73440750,
                86280293,
                133121268,
                156757775
            ],
            "dScore": 0.812,
            "gScore": 0.375,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "TUBA3D": "mutated"
                },
                "coherence": {
                    "TUBA3D": "TUBA3D is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "TUBA3D",
                    "entrezId": [
                        113457
                    ]
                }
            ],
            "family": [
                "tubulin polymerization inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [
                "BREAST",
                "ESOPHAGUS",
                "HEAD_AND_NECK",
                "LUNG",
                "PROSTATE",
                "STOMACH"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "DOCETAXEL TRIHYDRATE",
                    "showDrugName": "DOCETAXEL TRIHYDRATE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in TUBA3D are associated with response to DOCETAXEL TRIHYDRATE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.375,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "TUBA3D",
                            "entrezId": [
                                113457
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "ESOPHAGUS",
                        "HEAD_AND_NECK",
                        "LUNG",
                        "PROSTATE",
                        "STOMACH"
                    ],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "tubulin polymerization inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ERIBULIN MESYLATE",
            "showDrugName": "ERIBULIN MESYLATE",
            "status": "APPROVED",
            "statusDescription": "Approved for breast and fatty tissue cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                11354606,
                17755248
            ],
            "dScore": 0.812,
            "gScore": 0.375,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "TUBA3D": "mutated"
                },
                "coherence": {
                    "TUBA3D": "TUBA3D is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "TUBA3D",
                    "entrezId": [
                        113457
                    ]
                }
            ],
            "family": [
                "microtubule inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [
                "BREAST",
                "FATTY_TISSUE"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ERIBULIN MESYLATE",
                    "showDrugName": "ERIBULIN MESYLATE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in TUBA3D are associated with response to ERIBULIN MESYLATE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.375,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "TUBA3D",
                            "entrezId": [
                                113457
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "FATTY_TISSUE"
                    ],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "microtubule inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "IXABEPILONE",
            "showDrugName": "IXABEPILONE",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                6445540
            ],
            "dScore": 0.812,
            "gScore": 0.375,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "TUBA3D": "mutated"
                },
                "coherence": {
                    "TUBA3D": "TUBA3D is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "TUBA3D",
                    "entrezId": [
                        113457
                    ]
                }
            ],
            "family": [
                "microtubule stabilizing agent(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "IXABEPILONE",
                    "showDrugName": "IXABEPILONE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in TUBA3D are associated with response to IXABEPILONE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.375,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "TUBA3D",
                            "entrezId": [
                                113457
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "microtubule stabilizing agent(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TRASTUZUMAB EMTANSINE",
            "showDrugName": "TRASTUZUMAB EMTANSINE",
            "status": "APPROVED",
            "statusDescription": "Approved for breast, esophagus and stomach cancer",
            "therapy": "TARGETED_THERAPY",
            "target": false,
            "pubchemId": [],
            "dScore": 0.812,
            "gScore": 0.375,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "TUBA3D": "mutated"
                },
                "coherence": {
                    "TUBA3D": "TUBA3D is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "TUBA3D",
                    "entrezId": [
                        113457
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [
                "BREAST",
                "ESOPHAGUS",
                "STOMACH"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TRASTUZUMAB EMTANSINE",
                    "showDrugName": "TRASTUZUMAB EMTANSINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in TUBA3D are associated with response to TRASTUZUMAB EMTANSINE, a drug approved by FDA",
                    "therapy": "TARGETED_THERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.812,
                    "gScore": 0.375,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "TUBA3D",
                            "entrezId": [
                                113457
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "ESOPHAGUS",
                        "STOMACH"
                    ],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CAPECITABINE",
            "showDrugName": "CAPECITABINE",
            "status": "APPROVED",
            "statusDescription": "Approved for breast, colon, rectum and stomach cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                60953
            ],
            "dScore": 0.811,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "DNA synthesis inhibitor(Cmap)",
                "thymidylate synthase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [
                "BREAST",
                "COLON",
                "RECTUM",
                "STOMACH"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CAPECITABINE",
                    "showDrugName": "CAPECITABINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to CAPECITABINE, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.811,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST",
                        "COLON",
                        "RECTUM",
                        "STOMACH"
                    ],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "DNA synthesis inhibitor(Cmap)",
                        "thymidylate synthase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "EPIRUBICIN",
            "showDrugName": "EPIRUBICIN",
            "status": "APPROVED",
            "statusDescription": "Approved for breast cancer",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                41867
            ],
            "dScore": 0.811,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "topoisomerase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GDSC",
                    "link": "http://www.cancerrxgene.org/translation/Gene/GDSC",
                    "name": "GDSC"
                }
            ],
            "curatedSource": [],
            "cancer": [
                "BREAST"
            ],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "EPIRUBICIN",
                    "showDrugName": "EPIRUBICIN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to EPIRUBICIN, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.811,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [
                        "BREAST"
                    ],
                    "source": [
                        "GDSC"
                    ],
                    "family": [
                        "topoisomerase inhibitor(Cmap)"
                    ],
                    "alteration": [
                        {
                            "gene": "BRAF",
                            "alteration": "mutation",
                            "drugSource": "GDSC"
                        }
                    ],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "AMITRIPTYLINE",
            "showDrugName": "AMITRIPTYLINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2160
            ],
            "dScore": 0.3330000000000001,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "NTRK1": "mutated",
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "NTRK1": "NTRK1 is mutated",
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                }
            ],
            "family": [
                "norepinephrine inhibitor(Cmap)",
                "norepinephrine reuptake inhibitor(Cmap)",
                "serotonin receptor antagonist(Cmap)",
                "serotoninnorepinephrine reuptake inhibitor (SNRI)(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "AMITRIPTYLINE",
                    "showDrugName": "AMITRIPTYLINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "AMITRIPTYLINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.3330000000000001,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "norepinephrine inhibitor(Cmap)",
                        "norepinephrine reuptake inhibitor(Cmap)",
                        "serotonin receptor antagonist(Cmap)",
                        "serotoninnorepinephrine reuptake inhibitor (SNRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "AMITRIPTYLINE",
                    "showDrugName": "AMITRIPTYLINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "AMITRIPTYLINE is a drug approved by FDA that acts as an inhibitor of NTRK1",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.3320000000000001,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "norepinephrine inhibitor(Cmap)",
                        "norepinephrine reuptake inhibitor(Cmap)",
                        "serotonin receptor antagonist(Cmap)",
                        "serotoninnorepinephrine reuptake inhibitor (SNRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "AMITRIPTYLINE",
                    "showDrugName": "AMITRIPTYLINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "AMITRIPTYLINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.3320000000000001,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "norepinephrine inhibitor(Cmap)",
                        "norepinephrine reuptake inhibitor(Cmap)",
                        "serotonin receptor antagonist(Cmap)",
                        "serotoninnorepinephrine reuptake inhibitor (SNRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ARIPIPRAZOLE",
            "showDrugName": "ARIPIPRAZOLE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                60795
            ],
            "dScore": 0.32600000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ARIPIPRAZOLE",
                    "showDrugName": "ARIPIPRAZOLE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ARIPIPRAZOLE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32600000000000007,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ARIPIPRAZOLE",
                    "showDrugName": "ARIPIPRAZOLE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ARIPIPRAZOLE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32300000000000006,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SUMATRIPTAN",
            "showDrugName": "SUMATRIPTAN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5358
            ],
            "dScore": 0.32600000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "SUMATRIPTAN",
                    "showDrugName": "SUMATRIPTAN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "SUMATRIPTAN is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32600000000000007,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "SUMATRIPTAN",
                    "showDrugName": "SUMATRIPTAN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to SUMATRIPTAN, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.22099999999999997,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ZOLMITRIPTAN",
            "showDrugName": "ZOLMITRIPTAN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                60857
            ],
            "dScore": 0.32600000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ZOLMITRIPTAN",
                    "showDrugName": "ZOLMITRIPTAN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ZOLMITRIPTAN is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32600000000000007,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ZOLMITRIPTAN",
                    "showDrugName": "ZOLMITRIPTAN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ZOLMITRIPTAN is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LOXAPINE",
            "showDrugName": "LOXAPINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3964
            ],
            "dScore": 0.32500000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LOXAPINE",
                    "showDrugName": "LOXAPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LOXAPINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32500000000000007,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "LOXAPINE",
                    "showDrugName": "LOXAPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LOXAPINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "QUETIAPINE",
            "showDrugName": "QUETIAPINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5002
            ],
            "dScore": 0.32500000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "QUETIAPINE",
                    "showDrugName": "QUETIAPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "QUETIAPINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32500000000000007,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "QUETIAPINE",
                    "showDrugName": "QUETIAPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "QUETIAPINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ZIPRASIDONE",
            "showDrugName": "ZIPRASIDONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                60854
            ],
            "dScore": 0.32500000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ZIPRASIDONE",
                    "showDrugName": "ZIPRASIDONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ZIPRASIDONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32500000000000007,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ZIPRASIDONE",
                    "showDrugName": "ZIPRASIDONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ZIPRASIDONE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32300000000000006,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ASENAPINE",
            "showDrugName": "ASENAPINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                163091,
                3036780,
                9903970
            ],
            "dScore": 0.32400000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ASENAPINE",
                    "showDrugName": "ASENAPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ASENAPINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32400000000000007,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ASENAPINE",
                    "showDrugName": "ASENAPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ASENAPINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32400000000000007,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DIHYDROERGOTAMINE",
            "showDrugName": "DIHYDROERGOTAMINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                10531
            ],
            "dScore": 0.32400000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "DIHYDROERGOTAMINE",
                    "showDrugName": "DIHYDROERGOTAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DIHYDROERGOTAMINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32400000000000007,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DIHYDROERGOTAMINE",
                    "showDrugName": "DIHYDROERGOTAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DIHYDROERGOTAMINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ERGOTAMINE",
            "showDrugName": "ERGOTAMINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                8223
            ],
            "dScore": 0.32400000000000007,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ERGOTAMINE",
                    "showDrugName": "ERGOTAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ERGOTAMINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32400000000000007,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ERGOTAMINE",
                    "showDrugName": "ERGOTAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ERGOTAMINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32300000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ARIPIPRAZOLE LAUROXIL",
            "showDrugName": "ARIPIPRAZOLE LAUROXIL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                49831411
            ],
            "dScore": 0.32300000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ARIPIPRAZOLE LAUROXIL",
                    "showDrugName": "ARIPIPRAZOLE LAUROXIL",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ARIPIPRAZOLE LAUROXIL is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32300000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ARIPIPRAZOLE LAUROXIL",
                    "showDrugName": "ARIPIPRAZOLE LAUROXIL",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ARIPIPRAZOLE LAUROXIL is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BROMOCRIPTINE",
            "showDrugName": "BROMOCRIPTINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                31101
            ],
            "dScore": 0.32300000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "BROMOCRIPTINE",
                    "showDrugName": "BROMOCRIPTINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "BROMOCRIPTINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32300000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "BROMOCRIPTINE",
                    "showDrugName": "BROMOCRIPTINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "BROMOCRIPTINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32300000000000006,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "AMOXAPINE",
            "showDrugName": "AMOXAPINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2170
            ],
            "dScore": 0.32200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "norepinephrine reputake inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "AMOXAPINE",
                    "showDrugName": "AMOXAPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "AMOXAPINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "norepinephrine reputake inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "AMOXAPINE",
                    "showDrugName": "AMOXAPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "AMOXAPINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "norepinephrine reputake inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CANNABIDIOL",
            "showDrugName": "CANNABIDIOL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                644019
            ],
            "dScore": 0.32200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CANNABIDIOL",
                    "showDrugName": "CANNABIDIOL",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CANNABIDIOL is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CANNABIDIOL",
                    "showDrugName": "CANNABIDIOL",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CANNABIDIOL is a drug approved by FDA that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CLOMIPRAMINE",
            "showDrugName": "CLOMIPRAMINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2801
            ],
            "dScore": 0.32200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "serotonin transporter (SERT) inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DTC",
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CLOMIPRAMINE",
                    "showDrugName": "CLOMIPRAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CLOMIPRAMINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "serotonin transporter (SERT) inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CLOMIPRAMINE",
                    "showDrugName": "CLOMIPRAMINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to CLOMIPRAMINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.22199999999999998,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "serotonin transporter (SERT) inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LAMOTRIGINE",
            "showDrugName": "LAMOTRIGINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3878
            ],
            "dScore": 0.32200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "serotonin receptor antagonist(Cmap)",
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LAMOTRIGINE",
                    "showDrugName": "LAMOTRIGINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LAMOTRIGINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "serotonin receptor antagonist(Cmap)",
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LAMOTRIGINE",
                    "showDrugName": "LAMOTRIGINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to LAMOTRIGINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.22199999999999998,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "serotonin receptor antagonist(Cmap)",
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PINDOLOL",
            "showDrugName": "PINDOLOL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4828
            ],
            "dScore": 0.32200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "PINDOLOL",
                    "showDrugName": "PINDOLOL",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PINDOLOL is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PINDOLOL",
                    "showDrugName": "PINDOLOL",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to PINDOLOL, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.22199999999999998,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "OCRIPLASMIN",
            "showDrugName": "OCRIPLASMIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.32200000000000006,
            "gScore": 0.3886,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "COL1A1": "mutated",
                    "SERPINF2": "mutated"
                },
                "coherence": {
                    "COL1A1": "COL1A1 (oncogene) is mutated",
                    "SERPINF2": "SERPINF2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "COL1A1",
                    "entrezId": [
                        1277
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SERPINF2",
                    "entrezId": [
                        5345
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "OCRIPLASMIN",
                    "showDrugName": "OCRIPLASMIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "OCRIPLASMIN is a drug approved by FDA that acts as an inhibitor of SERPINF2",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3886,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SERPINF2",
                            "entrezId": [
                                5345
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "OCRIPLASMIN",
                    "showDrugName": "OCRIPLASMIN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in COL1A1 are associated with response to OCRIPLASMIN, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.22199999999999998,
                    "gScore": 0.3646,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "COL1A1",
                            "entrezId": [
                                1277
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "VONICOG ALFA",
            "showDrugName": "VONICOG ALFA",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.32200000000000006,
            "gScore": 0.3833,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "COL1A1": "mutated",
                    "F8": "mutated"
                },
                "coherence": {
                    "COL1A1": "COL1A1 (oncogene) is mutated",
                    "F8": "F8 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "COL1A1",
                    "entrezId": [
                        1277
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "F8",
                    "entrezId": [
                        2157
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "VONICOG ALFA",
                    "showDrugName": "VONICOG ALFA",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "VONICOG ALFA is a drug approved by FDA that acts as an inhibitor of F8",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3833,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "F8",
                            "entrezId": [
                                2157
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "VONICOG ALFA",
                    "showDrugName": "VONICOG ALFA",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "VONICOG ALFA is a drug approved by FDA that acts as an inhibitor of COL1A1",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.32200000000000006,
                    "gScore": 0.3646,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "COL1A1",
                            "entrezId": [
                                1277
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RISPERIDONE",
            "showDrugName": "RISPERIDONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5073
            ],
            "dScore": 0.31600000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "RISPERIDONE",
                    "showDrugName": "RISPERIDONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "RISPERIDONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31600000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "PharmGKB",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LIDOCAINE",
            "showDrugName": "LIDOCAINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3676
            ],
            "dScore": 0.31600000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "histamine receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LIDOCAINE",
                    "showDrugName": "LIDOCAINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LIDOCAINE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31600000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "PharmGKB",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "histamine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BENRALIZUMAB",
            "showDrugName": "BENRALIZUMAB",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.31500000000000006,
            "gScore": 0.5622,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "IL5RA": "mutated"
                },
                "coherence": {
                    "IL5RA": "IL5RA is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "IL5RA",
                    "entrezId": [
                        3568
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "SAbD",
                    "link": "http://opig.stats.ox.ac.uk/webapps/newsabdab/therasabdab/search/?therapeutic=BENRALIZUMAB",
                    "name": "SAbDab"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "BENRALIZUMAB",
                    "showDrugName": "BENRALIZUMAB",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "BENRALIZUMAB is a drug approved by FDA that acts as an inhibitor of IL5RA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31500000000000006,
                    "gScore": 0.5622,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "IL5RA",
                            "entrezId": [
                                3568
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "SAbDab",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LUMATEPERONE",
            "showDrugName": "LUMATEPERONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                21302490
            ],
            "dScore": 0.31500000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor modulator(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LUMATEPERONE",
                    "showDrugName": "LUMATEPERONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LUMATEPERONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31500000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor modulator(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NEFAZODONE",
            "showDrugName": "NEFAZODONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4449
            ],
            "dScore": 0.31500000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic inhibitor(Cmap)",
                "norepinephrine reuptake inhibitor(Cmap)",
                "serotonin receptor antagonist(Cmap)",
                "serotonin reuptake inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "NEFAZODONE",
                    "showDrugName": "NEFAZODONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "NEFAZODONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31500000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "adrenergic inhibitor(Cmap)",
                        "norepinephrine reuptake inhibitor(Cmap)",
                        "serotonin receptor antagonist(Cmap)",
                        "serotonin reuptake inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PALIPERIDONE",
            "showDrugName": "PALIPERIDONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                115237
            ],
            "dScore": 0.31500000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PALIPERIDONE",
                    "showDrugName": "PALIPERIDONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PALIPERIDONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31500000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TRAZODONE",
            "showDrugName": "TRAZODONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5533
            ],
            "dScore": 0.31500000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)",
                "serotonin reuptake inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TRAZODONE",
                    "showDrugName": "TRAZODONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "TRAZODONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31500000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)",
                        "serotonin reuptake inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FLUVASTATIN",
            "showDrugName": "FLUVASTATIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                446155,
                23663976,
                37888681
            ],
            "dScore": 0.31500000000000006,
            "gScore": 0.3127,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                }
            ],
            "family": [
                "HMGCR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FLUVASTATIN",
                    "showDrugName": "FLUVASTATIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FLUVASTATIN is a drug approved by FDA that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31500000000000006,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "PharmGKB",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "HMGCR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PHENYTOIN",
            "showDrugName": "PHENYTOIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                1775
            ],
            "dScore": 0.31500000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "hydantoin antiepileptic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PHENYTOIN",
                    "showDrugName": "PHENYTOIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PHENYTOIN is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31500000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "hydantoin antiepileptic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PRILOCAINE",
            "showDrugName": "PRILOCAINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4906
            ],
            "dScore": 0.31500000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "local anesthetic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PRILOCAINE",
                    "showDrugName": "PRILOCAINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PRILOCAINE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31500000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "local anesthetic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BREXPIPRAZOLE",
            "showDrugName": "BREXPIPRAZOLE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11978813
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor partial agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "BREXPIPRAZOLE",
                    "showDrugName": "BREXPIPRAZOLE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "BREXPIPRAZOLE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor partial agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CHLORPROMAZINE",
            "showDrugName": "CHLORPROMAZINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2726
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CHLORPROMAZINE",
                    "showDrugName": "CHLORPROMAZINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CHLORPROMAZINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CYCLOBENZAPRINE",
            "showDrugName": "CYCLOBENZAPRINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2895
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic receptor agonist(Cmap)",
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CYCLOBENZAPRINE",
                    "showDrugName": "CYCLOBENZAPRINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CYCLOBENZAPRINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "adrenergic receptor agonist(Cmap)",
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CYPROHEPTADINE",
            "showDrugName": "CYPROHEPTADINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2913
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "histamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CYPROHEPTADINE",
                    "showDrugName": "CYPROHEPTADINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CYPROHEPTADINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "histamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FLIBANSERIN",
            "showDrugName": "FLIBANSERIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                6918248
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FLIBANSERIN",
                    "showDrugName": "FLIBANSERIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FLIBANSERIN is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ILOPERIDONE",
            "showDrugName": "ILOPERIDONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                71360
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ILOPERIDONE",
                    "showDrugName": "ILOPERIDONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ILOPERIDONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PIMAVANSERIN",
            "showDrugName": "PIMAVANSERIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                10071196
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor inverse agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PIMAVANSERIN",
                    "showDrugName": "PIMAVANSERIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PIMAVANSERIN is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor inverse agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "THIOTHIXENE",
            "showDrugName": "TIOTIXENE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                941651
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "THIOTHIXENE",
                    "showDrugName": "TIOTIXENE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "TIOTIXENE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PITAVASTATIN",
            "showDrugName": "PITAVASTATIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5282452
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.3127,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                }
            ],
            "family": [
                "HMGCR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PITAVASTATIN",
                    "showDrugName": "PITAVASTATIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PITAVASTATIN is a drug approved by FDA that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "HMGCR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BENZONATATE",
            "showDrugName": "BENZONATATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                7699
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "local anesthetic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "BENZONATATE",
                    "showDrugName": "BENZONATATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "BENZONATATE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "local anesthetic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CARBAMAZEPINE",
            "showDrugName": "CARBAMAZEPINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2554
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "carboxamide antiepileptic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CARBAMAZEPINE",
                    "showDrugName": "CARBAMAZEPINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CARBAMAZEPINE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "carboxamide antiepileptic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DISOPYRAMIDE",
            "showDrugName": "DISOPYRAMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3114
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DISOPYRAMIDE",
                    "showDrugName": "DISOPYRAMIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DISOPYRAMIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "PharmGKB",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FLECAINIDE",
            "showDrugName": "FLECAINIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3356
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FLECAINIDE",
                    "showDrugName": "FLECAINIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FLECAINIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "PharmGKB",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FOSPHENYTOIN",
            "showDrugName": "FOSPHENYTOIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                56339
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FOSPHENYTOIN",
                    "showDrugName": "FOSPHENYTOIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FOSPHENYTOIN is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MEXILETINE",
            "showDrugName": "MEXILETINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4178
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "MEXILETINE",
                    "showDrugName": "MEXILETINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "MEXILETINE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "PharmGKB",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PROCAINAMIDE",
            "showDrugName": "PROCAINAMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4913
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PROCAINAMIDE",
                    "showDrugName": "PROCAINAMIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PROCAINAMIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "PharmGKB",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PROPAFENONE",
            "showDrugName": "PROPAFENONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4932
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "antiarrhythmic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PROPAFENONE",
                    "showDrugName": "PROPAFENONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PROPAFENONE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "PharmGKB",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "antiarrhythmic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "QUINIDINE",
            "showDrugName": "QUINIDINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                441074,
                68638786
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "QUINIDINE",
                    "showDrugName": "QUINIDINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "QUINIDINE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "PharmGKB",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ZONISAMIDE",
            "showDrugName": "ZONISAMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5734
            ],
            "dScore": 0.31400000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "T-type calcium channel blocker(Cmap)",
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ZONISAMIDE",
                    "showDrugName": "ZONISAMIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ZONISAMIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31400000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "T-type calcium channel blocker(Cmap)",
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DOXEPIN",
            "showDrugName": "DOXEPIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3158,
                667468,
                667477
            ],
            "dScore": 0.31300000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "histamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DOXEPIN",
                    "showDrugName": "DOXEPIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DOXEPIN is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31300000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "histamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LURASIDONE",
            "showDrugName": "LURASIDONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                213046
            ],
            "dScore": 0.31300000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LURASIDONE",
                    "showDrugName": "LURASIDONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LURASIDONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31300000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MOLINDONE",
            "showDrugName": "MOLINDONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                23897
            ],
            "dScore": 0.31300000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "MOLINDONE",
                    "showDrugName": "MOLINDONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "MOLINDONE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31300000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "COCAINE",
            "showDrugName": "COCAINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                446220
            ],
            "dScore": 0.31300000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "COCAINE",
                    "showDrugName": "COCAINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "COCAINE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31300000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "AMISULPRIDE",
            "showDrugName": "AMISULPRIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2159
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "AMISULPRIDE",
                    "showDrugName": "AMISULPRIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "AMISULPRIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ASENAPINE MALEATE",
            "showDrugName": "ASENAPINE MALEATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                163091,
                6917875,
                57354691,
                71311991
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ASENAPINE MALEATE",
                    "showDrugName": "ASENAPINE MALEATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ASENAPINE MALEATE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CARIPRAZINE",
            "showDrugName": "CARIPRAZINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11154555
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CARIPRAZINE",
                    "showDrugName": "CARIPRAZINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CARIPRAZINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CHLORPROMAZINE HYDROCHLORIDE",
            "showDrugName": "CHLORPROMAZINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                6240
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CHLORPROMAZINE HYDROCHLORIDE",
                    "showDrugName": "CHLORPROMAZINE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CHLORPROMAZINE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CYCLOBENZAPRINE HYDROCHLORIDE",
            "showDrugName": "CYCLOBENZAPRINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                22576
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic receptor agonist(Cmap)",
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CYCLOBENZAPRINE HYDROCHLORIDE",
                    "showDrugName": "CYCLOBENZAPRINE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CYCLOBENZAPRINE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "TTD"
                    ],
                    "family": [
                        "adrenergic receptor agonist(Cmap)",
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DESIPRAMINE",
            "showDrugName": "DESIPRAMINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                2995
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "tricyclic antidepressant(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DESIPRAMINE",
                    "showDrugName": "DESIPRAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DESIPRAMINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "tricyclic antidepressant(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DONEPEZIL",
            "showDrugName": "DONEPEZIL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3152
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "acetylcholinesterase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DONEPEZIL",
                    "showDrugName": "DONEPEZIL",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DONEPEZIL is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "acetylcholinesterase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "EPINASTINE",
            "showDrugName": "EPINASTINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3241
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "histamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "EPINASTINE",
                    "showDrugName": "EPINASTINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "EPINASTINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "histamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FENFLURAMINE",
            "showDrugName": "FENFLURAMINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3337
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FENFLURAMINE",
                    "showDrugName": "FENFLURAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FENFLURAMINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "HALOPERIDOL DECANOATE",
            "showDrugName": "HALOPERIDOL DECANOATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                52919
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "HALOPERIDOL DECANOATE",
                    "showDrugName": "HALOPERIDOL DECANOATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "HALOPERIDOL DECANOATE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "KETAMINE",
            "showDrugName": "KETAMINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3821
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "KETAMINE",
                    "showDrugName": "KETAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "KETAMINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LOXAPINE HYDROCHLORIDE",
            "showDrugName": "LOXAPINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                71400
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LOXAPINE HYDROCHLORIDE",
                    "showDrugName": "LOXAPINE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LOXAPINE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LOXAPINE SUCCINATE",
            "showDrugName": "LOXAPINE SUCCINATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                71399
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LOXAPINE SUCCINATE",
                    "showDrugName": "LOXAPINE SUCCINATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LOXAPINE SUCCINATE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LURASIDONE HYDROCHLORIDE",
            "showDrugName": "LURASIDONE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11237860
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LURASIDONE HYDROCHLORIDE",
                    "showDrugName": "LURASIDONE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LURASIDONE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MOLINDONE HYDROCHLORIDE",
            "showDrugName": "MOLINDONE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                9883259
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "MOLINDONE HYDROCHLORIDE",
                    "showDrugName": "MOLINDONE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "MOLINDONE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NEFAZODONE HYDROCHLORIDE",
            "showDrugName": "NEFAZODONE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                54911
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic inhibitor(Cmap)",
                "norepinephrine reuptake inhibitor(Cmap)",
                "serotonin receptor antagonist(Cmap)",
                "serotonin reuptake inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "NEFAZODONE HYDROCHLORIDE",
                    "showDrugName": "NEFAZODONE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "NEFAZODONE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "adrenergic inhibitor(Cmap)",
                        "norepinephrine reuptake inhibitor(Cmap)",
                        "serotonin receptor antagonist(Cmap)",
                        "serotonin reuptake inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NORTRIPTYLINE",
            "showDrugName": "NORTRIPTYLINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4543
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "tricyclic antidepressant(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "NORTRIPTYLINE",
                    "showDrugName": "NORTRIPTYLINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "NORTRIPTYLINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "tricyclic antidepressant(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PAROXETINE",
            "showDrugName": "PAROXETINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                43815
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "selective serotonin reuptake inhibitor (SSRI)(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PAROXETINE",
                    "showDrugName": "PAROXETINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PAROXETINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "PharmGKB"
                    ],
                    "family": [
                        "selective serotonin reuptake inhibitor (SSRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PERPHENAZINE",
            "showDrugName": "PERPHENAZINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4748
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PERPHENAZINE",
                    "showDrugName": "PERPHENAZINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PERPHENAZINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PIMAVANSERIN TARTRATE",
            "showDrugName": "PIMAVANSERIN TARTRATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11672491
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor inverse agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PIMAVANSERIN TARTRATE",
                    "showDrugName": "PIMAVANSERIN TARTRATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PIMAVANSERIN TARTRATE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "serotonin receptor inverse agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PROCHLORPERAZINE",
            "showDrugName": "PROCHLORPERAZINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4917
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                }
            ],
            "curatedSource": [
                "TEND"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PROCHLORPERAZINE",
                    "showDrugName": "PROCHLORPERAZINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PROCHLORPERAZINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TEND"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "QUETIAPINE FUMARATE",
            "showDrugName": "QUETIAPINE FUMARATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5002,
                73286,
                441261,
                5281025,
                6918224,
                25058200,
                45358180
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "QUETIAPINE FUMARATE",
                    "showDrugName": "QUETIAPINE FUMARATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "QUETIAPINE FUMARATE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TRAZODONE HYDROCHLORIDE",
            "showDrugName": "TRAZODONE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                62935
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)",
                "serotonin reuptake inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TRAZODONE HYDROCHLORIDE",
                    "showDrugName": "TRAZODONE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "TRAZODONE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)",
                        "serotonin reuptake inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TRIMIPRAMINE",
            "showDrugName": "TRIMIPRAMINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5584
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "norepinephrine reputake inhibitor(Cmap)",
                "tricyclic antidepressant(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TRIMIPRAMINE",
                    "showDrugName": "TRIMIPRAMINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "TRIMIPRAMINE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "norepinephrine reputake inhibitor(Cmap)",
                        "tricyclic antidepressant(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TRIMIPRAMINE MALEATE",
            "showDrugName": "TRIMIPRAMINE MALEATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5282318
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "norepinephrine reputake inhibitor(Cmap)",
                "tricyclic antidepressant(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TRIMIPRAMINE MALEATE",
                    "showDrugName": "TRIMIPRAMINE MALEATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "TRIMIPRAMINE MALEATE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "norepinephrine reputake inhibitor(Cmap)",
                        "tricyclic antidepressant(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ZIPRASIDONE HYDROCHLORIDE",
            "showDrugName": "ZIPRASIDONE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                219099
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ZIPRASIDONE HYDROCHLORIDE",
                    "showDrugName": "ZIPRASIDONE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ZIPRASIDONE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ZIPRASIDONE MESYLATE",
            "showDrugName": "ZIPRASIDONE MESYLATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                154068,
                656685
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ZIPRASIDONE MESYLATE",
                    "showDrugName": "ZIPRASIDONE MESYLATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ZIPRASIDONE MESYLATE is a drug approved by FDA that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CENEGERMIN",
            "showDrugName": "CENEGERMIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.31200000000000006,
            "gScore": 0.4509,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "NTRK1": "mutated"
                },
                "coherence": {
                    "NTRK1": "NTRK1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "CENEGERMIN",
                    "showDrugName": "CENEGERMIN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "CENEGERMIN is a drug approved by FDA that acts as an inhibitor of NTRK1",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DAMOCTOCOG ALFA PEGOL",
            "showDrugName": "DAMOCTOCOG ALFA PEGOL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                86278352
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.3833,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "F8": "mutated"
                },
                "coherence": {
                    "F8": "F8 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "F8",
                    "entrezId": [
                        2157
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DAMOCTOCOG ALFA PEGOL",
                    "showDrugName": "DAMOCTOCOG ALFA PEGOL",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DAMOCTOCOG ALFA PEGOL is a drug approved by FDA that acts as an inhibitor of F8",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.3833,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "F8",
                            "entrezId": [
                                2157
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NONACOG BETA PEGOL",
            "showDrugName": "NONACOG BETA PEGOL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.31200000000000006,
            "gScore": 0.3833,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "F8": "mutated"
                },
                "coherence": {
                    "F8": "F8 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "F8",
                    "entrezId": [
                        2157
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "NONACOG BETA PEGOL",
                    "showDrugName": "NONACOG BETA PEGOL",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "NONACOG BETA PEGOL is a drug approved by FDA that acts as an inhibitor of F8",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.3833,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "F8",
                            "entrezId": [
                                2157
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TITANIUM DIOXIDE",
            "showDrugName": "TITANIUM DIOXIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                26042
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.3626,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "MARCO": "mutated"
                },
                "coherence": {
                    "MARCO": "MARCO is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "MARCO",
                    "entrezId": [
                        8685
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TITANIUM DIOXIDE",
                    "showDrugName": "TITANIUM DIOXIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "TITANIUM DIOXIDE is a drug approved by FDA that acts as an inhibitor of MARCO",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.3626,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "MARCO",
                            "entrezId": [
                                8685
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ATORVASTATIN CALCIUM",
            "showDrugName": "ATORVASTATIN CALCIUM",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                60822,
                60823,
                656846,
                9833468,
                11227182,
                15378998,
                17589822,
                45790066,
                101610369
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.3127,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                }
            ],
            "family": [
                "HMGCR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ATORVASTATIN CALCIUM",
                    "showDrugName": "ATORVASTATIN CALCIUM",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ATORVASTATIN CALCIUM is a drug approved by FDA that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "HMGCR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FLUVASTATIN SODIUM",
            "showDrugName": "FLUVASTATIN SODIUM",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                16760425,
                23663976,
                23679527,
                24906289,
                66587062
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.3127,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                }
            ],
            "family": [
                "HMGCR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FLUVASTATIN SODIUM",
                    "showDrugName": "FLUVASTATIN SODIUM",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FLUVASTATIN SODIUM is a drug approved by FDA that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "HMGCR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PITAVASTATIN CALCIUM",
            "showDrugName": "PITAVASTATIN CALCIUM",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5282451,
                5282452,
                9847241,
                9955951,
                11251522,
                24848419
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.3127,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                }
            ],
            "family": [
                "HMGCR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PITAVASTATIN CALCIUM",
                    "showDrugName": "PITAVASTATIN CALCIUM",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PITAVASTATIN CALCIUM is a drug approved by FDA that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "HMGCR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ROSUVASTATIN CALCIUM",
            "showDrugName": "ROSUVASTATIN CALCIUM",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                446157,
                5282455,
                9869776,
                12086784,
                54613184
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.3127,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                }
            ],
            "family": [
                "HMGCR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ROSUVASTATIN CALCIUM",
                    "showDrugName": "ROSUVASTATIN CALCIUM",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ROSUVASTATIN CALCIUM is a drug approved by FDA that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "HMGCR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DISOPYRAMIDE PHOSPHATE",
            "showDrugName": "DISOPYRAMIDE PHOSPHATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                30928
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DISOPYRAMIDE PHOSPHATE",
                    "showDrugName": "DISOPYRAMIDE PHOSPHATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DISOPYRAMIDE PHOSPHATE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DRONEDARONE",
            "showDrugName": "DRONEDARONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                208898
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "adrenergic receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DRONEDARONE",
                    "showDrugName": "DRONEDARONE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DRONEDARONE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DRONEDARONE HYDROCHLORIDE",
            "showDrugName": "DRONEDARONE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                219025
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "adrenergic receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DRONEDARONE HYDROCHLORIDE",
                    "showDrugName": "DRONEDARONE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DRONEDARONE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DYCLONINE HYDROCHLORIDE",
            "showDrugName": "DYCLONINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                68304
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DYCLONINE HYDROCHLORIDE",
                    "showDrugName": "DYCLONINE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DYCLONINE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FLECAINIDE ACETATE",
            "showDrugName": "FLECAINIDE ACETATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                41022
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FLECAINIDE ACETATE",
                    "showDrugName": "FLECAINIDE ACETATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FLECAINIDE ACETATE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FOSPHENYTOIN SODIUM",
            "showDrugName": "FOSPHENYTOIN SODIUM",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                56338
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FOSPHENYTOIN SODIUM",
                    "showDrugName": "FOSPHENYTOIN SODIUM",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FOSPHENYTOIN SODIUM is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "6108-05-0",
            "showDrugName": "LIDOCAINE HYDROCHLORIDE HYDRATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                16219577
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "histamine receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "6108-05-0",
                    "showDrugName": "LIDOCAINE HYDROCHLORIDE HYDRATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "LIDOCAINE HYDROCHLORIDE HYDRATE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "histamine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MEXILETINE HYDROCHLORIDE",
            "showDrugName": "MEXILETINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                21467
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "MEXILETINE HYDROCHLORIDE",
                    "showDrugName": "MEXILETINE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "MEXILETINE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PHENYTOIN SODIUM",
            "showDrugName": "PHENYTOIN SODIUM",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                1775,
                4787,
                657302,
                9795547,
                13241308,
                21935075,
                23679632
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "hydantoin antiepileptic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PHENYTOIN SODIUM",
                    "showDrugName": "PHENYTOIN SODIUM",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PHENYTOIN SODIUM is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "hydantoin antiepileptic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PRILOCAINE HYDROCHLORIDE",
            "showDrugName": "PRILOCAINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                92163
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "local anesthetic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PRILOCAINE HYDROCHLORIDE",
                    "showDrugName": "PRILOCAINE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PRILOCAINE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "local anesthetic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PROCAINAMIDE HYDROCHLORIDE",
            "showDrugName": "PROCAINAMIDE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                66068
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PROCAINAMIDE HYDROCHLORIDE",
                    "showDrugName": "PROCAINAMIDE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PROCAINAMIDE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PROPAFENONE HYDROCHLORIDE",
            "showDrugName": "PROPAFENONE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                36708
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "antiarrhythmic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PROPAFENONE HYDROCHLORIDE",
                    "showDrugName": "PROPAFENONE HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "PROPAFENONE HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "antiarrhythmic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "QUINIDINE GLUCONATE",
            "showDrugName": "QUINIDINE GLUCONATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                94328
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "QUINIDINE GLUCONATE",
                    "showDrugName": "QUINIDINE GLUCONATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "QUINIDINE GLUCONATE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "QUINIDINE SULFATE",
            "showDrugName": "QUINIDINE SULFATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5768,
                5953,
                11069,
                441074,
                441326,
                656862,
                5748152,
                21954270,
                22817455,
                23424040,
                24867529,
                118705497,
                162639137
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "QUINIDINE SULFATE",
                    "showDrugName": "QUINIDINE SULFATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "QUINIDINE SULFATE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "VERNAKALANT",
            "showDrugName": "VERNAKALANT",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                9930049
            ],
            "dScore": 0.31200000000000006,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "potassium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "VERNAKALANT",
                    "showDrugName": "VERNAKALANT",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "VERNAKALANT is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31200000000000006,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "potassium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TERIFLUNOMIDE",
            "showDrugName": "TERIFLUNOMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                54684141
            ],
            "dScore": 0.31100000000000005,
            "gScore": 0.3127,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                }
            ],
            "family": [
                "dihydroorotate dehydrogenase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TERIFLUNOMIDE",
                    "showDrugName": "TERIFLUNOMIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "TERIFLUNOMIDE is a drug approved by FDA that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31100000000000005,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TTD"
                    ],
                    "family": [
                        "dihydroorotate dehydrogenase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DYCLONINE",
            "showDrugName": "DYCLONINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3180
            ],
            "dScore": 0.31100000000000005,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DYCLONINE",
                    "showDrugName": "DYCLONINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "DYCLONINE is a drug approved by FDA that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.31100000000000005,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TTD"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ALMOTRIPTAN",
            "showDrugName": "ALMOTRIPTAN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                123606
            ],
            "dScore": 0.30500000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ALMOTRIPTAN",
                    "showDrugName": "ALMOTRIPTAN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ALMOTRIPTAN is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30500000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FROVATRIPTAN",
            "showDrugName": "FROVATRIPTAN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                77992
            ],
            "dScore": 0.30500000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "FROVATRIPTAN",
                    "showDrugName": "FROVATRIPTAN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FROVATRIPTAN is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30500000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NARATRIPTAN",
            "showDrugName": "NARATRIPTAN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4440
            ],
            "dScore": 0.30500000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "NARATRIPTAN",
                    "showDrugName": "NARATRIPTAN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "NARATRIPTAN is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30500000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RIZATRIPTAN",
            "showDrugName": "RIZATRIPTAN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5078
            ],
            "dScore": 0.30500000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "RIZATRIPTAN",
                    "showDrugName": "RIZATRIPTAN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "RIZATRIPTAN is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30500000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ELETRIPTAN",
            "showDrugName": "ELETRIPTAN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                77993
            ],
            "dScore": 0.30400000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ELETRIPTAN",
                    "showDrugName": "ELETRIPTAN",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ELETRIPTAN is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30400000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TTD"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "OXYMETAZOLINE",
            "showDrugName": "OXYMETAZOLINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4636
            ],
            "dScore": 0.30300000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "adrenergic receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "OXYMETAZOLINE",
                    "showDrugName": "OXYMETAZOLINE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "OXYMETAZOLINE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30300000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "adrenergic receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "7440-66-6",
            "showDrugName": "ZINC",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                23994
            ],
            "dScore": 0.30200000000000005,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "7440-66-6",
                    "showDrugName": "ZINC",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ZINC is a drug approved by FDA that acts as an inhibitor of MDM2, a genetic dependency of BRAF gof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "ONC",
                            "geneSymbol": "MDM2",
                            "entrezId": [
                                4193
                            ]
                        },
                        "alterations": {
                            "BRAF": "gof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30200000000000005,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ALMOTRIPTAN MALATE",
            "showDrugName": "ALMOTRIPTAN MALATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                123607
            ],
            "dScore": 0.30200000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ALMOTRIPTAN MALATE",
                    "showDrugName": "ALMOTRIPTAN MALATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ALMOTRIPTAN MALATE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30200000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ELETRIPTAN HYDROBROMIDE",
            "showDrugName": "ELETRIPTAN HYDROBROMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                656631
            ],
            "dScore": 0.30200000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "ELETRIPTAN HYDROBROMIDE",
                    "showDrugName": "ELETRIPTAN HYDROBROMIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "ELETRIPTAN HYDROBROMIDE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30200000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "158930-17-7",
            "showDrugName": "FROVATRIPTAN SUCCINATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                152943
            ],
            "dScore": 0.30200000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "158930-17-7",
                    "showDrugName": "FROVATRIPTAN SUCCINATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "FROVATRIPTAN SUCCINATE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30200000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NARATRIPTAN HYDROCHLORIDE",
            "showDrugName": "NARATRIPTAN HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                60875
            ],
            "dScore": 0.30200000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "NARATRIPTAN HYDROCHLORIDE",
                    "showDrugName": "NARATRIPTAN HYDROCHLORIDE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "NARATRIPTAN HYDROCHLORIDE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30200000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RIZATRIPTAN BENZOATE",
            "showDrugName": "RIZATRIPTAN BENZOATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                77997
            ],
            "dScore": 0.30200000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "RIZATRIPTAN BENZOATE",
                    "showDrugName": "RIZATRIPTAN BENZOATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "RIZATRIPTAN BENZOATE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30200000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SUMATRIPTAN SUCCINATE",
            "showDrugName": "SUMATRIPTAN SUCCINATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": true,
            "pubchemId": [
                59772
            ],
            "dScore": 0.30200000000000005,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "serotonin receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "SUMATRIPTAN SUCCINATE",
                    "showDrugName": "SUMATRIPTAN SUCCINATE",
                    "target": "target",
                    "status": "APPROVED",
                    "drugStatusInfo": "SUMATRIPTAN SUCCINATE is a drug approved by FDA that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.30200000000000005,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "serotonin receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "33069-62-4",
            "showDrugName": "PACLITAXEL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": "CHEMOTHERAPY",
            "target": false,
            "pubchemId": [
                36314
            ],
            "dScore": 0.22299999999999998,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "TUBA3D": "mutated",
                    "PTEN": "mutated"
                },
                "coherence": {
                    "TUBA3D": "TUBA3D is mutated",
                    "PTEN": "PTEN (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "TUBA3D",
                    "entrezId": [
                        113457
                    ]
                }
            ],
            "family": [
                "tubulin polymerization inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DTC",
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "33069-62-4",
                    "showDrugName": "PACLITAXEL",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in TUBA3D are associated with response to PACLITAXEL, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.22299999999999998,
                    "gScore": 0.375,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "TUBA3D",
                            "entrezId": [
                                113457
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DTC"
                    ],
                    "family": [
                        "tubulin polymerization inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "33069-62-4",
                    "showDrugName": "PACLITAXEL",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to PACLITAXEL, a drug approved by FDA",
                    "therapy": "CHEMOTHERAPY",
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.22199999999999998,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "tubulin polymerization inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PIMOZIDE",
            "showDrugName": "PIMOZIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                16362
            ],
            "dScore": 0.213,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PIMOZIDE",
                    "showDrugName": "PIMOZIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to PIMOZIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.213,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ESLICARBAZEPINE",
            "showDrugName": "ESLICARBAZEPINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                9881504
            ],
            "dScore": 0.213,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ESLICARBAZEPINE",
                    "showDrugName": "ESLICARBAZEPINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to ESLICARBAZEPINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.213,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "AGOMELATINE",
            "showDrugName": "AGOMELATINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                82148
            ],
            "dScore": 0.212,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "melatonin receptor agonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "AGOMELATINE",
                    "showDrugName": "AGOMELATINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to AGOMELATINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "melatonin receptor agonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DROPERIDOL",
            "showDrugName": "DROPERIDOL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                3168
            ],
            "dScore": 0.212,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "DROPERIDOL",
                    "showDrugName": "DROPERIDOL",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to DROPERIDOL, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DULOXETINE",
            "showDrugName": "DULOXETINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                60835
            ],
            "dScore": 0.212,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "norepinephrine reuptake inhibitor(Cmap)",
                "serotoninnorepinephrine reuptake inhibitor (SNRI)(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "DULOXETINE",
                    "showDrugName": "DULOXETINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to DULOXETINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "norepinephrine reuptake inhibitor(Cmap)",
                        "serotoninnorepinephrine reuptake inhibitor (SNRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FLUOXETINE",
            "showDrugName": "FLUOXETINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                3386
            ],
            "dScore": 0.212,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "selective serotonin reuptake inhibitor (SSRI)(Cmap)"
            ],
            "source": [
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "FLUOXETINE",
                    "showDrugName": "FLUOXETINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to FLUOXETINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "selective serotonin reuptake inhibitor (SSRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "METHYLERGONOVINE",
            "showDrugName": "METHYLERGOMETRINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                8226
            ],
            "dScore": 0.212,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "METHYLERGONOVINE",
                    "showDrugName": "METHYLERGOMETRINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to METHYLERGOMETRINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TRIFLUOPERAZINE",
            "showDrugName": "TRIFLUOPERAZINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5566
            ],
            "dScore": 0.212,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TRIFLUOPERAZINE",
                    "showDrugName": "TRIFLUOPERAZINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to TRIFLUOPERAZINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TRIFLUOPERAZINE DIHYDROCHLORIDE",
            "showDrugName": "TRIFLUOPERAZINE DIHYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                66064
            ],
            "dScore": 0.212,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TRIFLUOPERAZINE DIHYDROCHLORIDE",
                    "showDrugName": "TRIFLUOPERAZINE DIHYDROCHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to TRIFLUOPERAZINE DIHYDROCHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SORBITOL",
            "showDrugName": "SORBITOL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5780
            ],
            "dScore": 0.212,
            "gScore": 0.3833,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "F8": "mutated"
                },
                "coherence": {
                    "F8": "F8 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "F8",
                    "entrezId": [
                        2157
                    ]
                }
            ],
            "family": [
                "mucolytic agent(Cmap)"
            ],
            "source": [
                {
                    "shortName": "NCI",
                    "link": "https://dgidb.genome.wustl.edu/sources/NCI",
                    "name": "NCI"
                }
            ],
            "curatedSource": [
                "NCI"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "SORBITOL",
                    "showDrugName": "SORBITOL",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in F8 are associated with response to SORBITOL, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.3833,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "F8",
                            "entrezId": [
                                2157
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "NCI"
                    ],
                    "family": [
                        "mucolytic agent(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FENOLDOPAM MESYLATE",
            "showDrugName": "FENOLDOPAM MESYLATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                49659
            ],
            "dScore": 0.212,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "dopamine receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "FENOLDOPAM MESYLATE",
                    "showDrugName": "FENOLDOPAM MESYLATE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to FENOLDOPAM MESYLATE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "dopamine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LEVODOPA",
            "showDrugName": "LEVODOPA",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                6047
            ],
            "dScore": 0.212,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "dopamine precursor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LEVODOPA",
                    "showDrugName": "LEVODOPA",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to LEVODOPA, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "dopamine precursor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MEFENAMIC ACID",
            "showDrugName": "MEFENAMIC ACID",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                4044
            ],
            "dScore": 0.212,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "MEFENAMIC ACID",
                    "showDrugName": "MEFENAMIC ACID",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to MEFENAMIC ACID, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "METHYLDOPA",
            "showDrugName": "METHYLDOPA",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                38853
            ],
            "dScore": 0.212,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "adrenergic receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "METHYLDOPA",
                    "showDrugName": "METHYLDOPA",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to METHYLDOPA, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "adrenergic receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "METHYLENE BLUE",
            "showDrugName": "METHYLTHIONINIUM CHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                6099
            ],
            "dScore": 0.212,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "METHYLENE BLUE",
                    "showDrugName": "METHYLTHIONINIUM CHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to METHYLTHIONINIUM CHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NOREPINEPHRINE",
            "showDrugName": "NOREPINEPHRINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                439260
            ],
            "dScore": 0.212,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "adrenergic receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "NOREPINEPHRINE",
                    "showDrugName": "NOREPINEPHRINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to NOREPINEPHRINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "adrenergic receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PODOPHYLLOTOXIN",
            "showDrugName": "PODOPHYLLOTOXIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                10607
            ],
            "dScore": 0.212,
            "gScore": 0.375,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "TUBA3D": "mutated"
                },
                "coherence": {
                    "TUBA3D": "TUBA3D is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "TUBA3D",
                    "entrezId": [
                        113457
                    ]
                }
            ],
            "family": [
                "microtubule inhibitor(Cmap)",
                "tubulin polymerization inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PODOPHYLLOTOXIN",
                    "showDrugName": "PODOPHYLLOTOXIN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in TUBA3D are associated with response to PODOPHYLLOTOXIN, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.375,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "TUBA3D",
                            "entrezId": [
                                113457
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "microtubule inhibitor(Cmap)",
                        "tubulin polymerization inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DOXYCYCLINE",
            "showDrugName": "DOXYCYCLINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                54671203
            ],
            "dScore": 0.212,
            "gScore": 0.3425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "F2RL1": "mutated"
                },
                "coherence": {
                    "F2RL1": "F2RL1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "F2RL1",
                    "entrezId": [
                        2150
                    ]
                }
            ],
            "family": [
                "bacterial 30S ribosomal subunit inhibitor(Cmap)",
                "metalloproteinase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "DOXYCYCLINE",
                    "showDrugName": "DOXYCYCLINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in F2RL1 are associated with response to DOXYCYCLINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.3425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "F2RL1",
                            "entrezId": [
                                2150
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "bacterial 30S ribosomal subunit inhibitor(Cmap)",
                        "metalloproteinase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CYCLOSPORIN A",
            "showDrugName": "CICLOSPORIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5284373
            ],
            "dScore": 0.212,
            "gScore": 0.2426,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "VCAN": "mutated"
                },
                "coherence": {
                    "VCAN": "VCAN is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "VCAN",
                    "entrezId": [
                        1462
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "NCI",
                    "link": "https://dgidb.genome.wustl.edu/sources/NCI",
                    "name": "NCI"
                }
            ],
            "curatedSource": [
                "NCI"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CYCLOSPORIN A",
                    "showDrugName": "CICLOSPORIN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in VCAN are associated with response to CICLOSPORIN, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2426,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "VCAN",
                            "entrezId": [
                                1462
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "NCI"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ARTICAINE HYDROCHLORIDE",
            "showDrugName": "ARTICAINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                32169
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "local anesthetic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ARTICAINE HYDROCHLORIDE",
                    "showDrugName": "ARTICAINE HYDROCHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to ARTICAINE HYDROCHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "local anesthetic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BENOXINATE HYDROCHLORIDE",
            "showDrugName": "BENOXINATE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                6420040
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "BENOXINATE HYDROCHLORIDE",
                    "showDrugName": "BENOXINATE HYDROCHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to BENOXINATE HYDROCHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BUPIVACAINE",
            "showDrugName": "BUPIVACAINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                2474
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "BUPIVACAINE",
                    "showDrugName": "BUPIVACAINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to BUPIVACAINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CHLOROPROCAINE HYDROCHLORIDE",
            "showDrugName": "CHLOROPROCAINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                441348
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CHLOROPROCAINE HYDROCHLORIDE",
                    "showDrugName": "CHLOROPROCAINE HYDROCHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to CHLOROPROCAINE HYDROCHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LACOSAMIDE",
            "showDrugName": "ERLOSAMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                219078
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LACOSAMIDE",
                    "showDrugName": "ERLOSAMIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to ERLOSAMIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ESLICARBAZEPINE ACETATE",
            "showDrugName": "ESLICARBAZEPINE ACETATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                179344
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ESLICARBAZEPINE ACETATE",
                    "showDrugName": "ESLICARBAZEPINE ACETATE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to ESLICARBAZEPINE ACETATE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MEPIVACAINE HYDROCHLORIDE",
            "showDrugName": "MEPIVACAINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                66070
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "potassium channel blocker(Cmap)",
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "MEPIVACAINE HYDROCHLORIDE",
                    "showDrugName": "MEPIVACAINE HYDROCHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to MEPIVACAINE HYDROCHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "potassium channel blocker(Cmap)",
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ORPHENADRINE",
            "showDrugName": "ORPHENADRINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                4601
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "acetylcholine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ORPHENADRINE",
                    "showDrugName": "ORPHENADRINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to ORPHENADRINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "acetylcholine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PRIMIDONE",
            "showDrugName": "PRIMIDONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                4909
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "GABA receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PRIMIDONE",
                    "showDrugName": "PRIMIDONE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to PRIMIDONE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "GABA receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PROPARACAINE HYDROCHLORIDE",
            "showDrugName": "PROPARACAINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                517321
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PROPARACAINE HYDROCHLORIDE",
                    "showDrugName": "PROPARACAINE HYDROCHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to PROPARACAINE HYDROCHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ROPIVACAINE",
            "showDrugName": "ROPIVACAINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                175805
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ROPIVACAINE",
                    "showDrugName": "ROPIVACAINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to ROPIVACAINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ROPIVACAINE HYDROCHLORIDE",
            "showDrugName": "ROPIVACAINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                175804,
                175805,
                6918111,
                46856340,
                53262281,
                53262295
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ROPIVACAINE HYDROCHLORIDE",
                    "showDrugName": "ROPIVACAINE HYDROCHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to ROPIVACAINE HYDROCHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RUFINAMIDE",
            "showDrugName": "RUFINAMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                129228
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "voltage-gated sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "RUFINAMIDE",
                    "showDrugName": "RUFINAMIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to RUFINAMIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "voltage-gated sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SAFINAMIDE",
            "showDrugName": "SAFINAMIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                131682
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "dopamine reuptake inhibitor(Cmap)",
                "glutamate inhibitor(Cmap)",
                "monoamine oxidase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "SAFINAMIDE",
                    "showDrugName": "SAFINAMIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to SAFINAMIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine reuptake inhibitor(Cmap)",
                        "glutamate inhibitor(Cmap)",
                        "monoamine oxidase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TETRACAINE",
            "showDrugName": "TETRACAINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5411
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "membrane integrity inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TETRACAINE",
                    "showDrugName": "TETRACAINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to TETRACAINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "membrane integrity inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TETRACAINE HYDROCHLORIDE",
            "showDrugName": "TETRACAINE HYDROCHLORIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                8695
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "membrane integrity inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TETRACAINE HYDROCHLORIDE",
                    "showDrugName": "TETRACAINE HYDROCHLORIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to TETRACAINE HYDROCHLORIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "membrane integrity inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TOPIRAMATE",
            "showDrugName": "TOPIRAMATE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5284627
            ],
            "dScore": 0.212,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "carbonic anhydrase inhibitor(Cmap)",
                "glutamate receptor antagonist(Cmap)",
                "kainate receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TOPIRAMATE",
                    "showDrugName": "TOPIRAMATE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to TOPIRAMATE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "carbonic anhydrase inhibitor(Cmap)",
                        "glutamate receptor antagonist(Cmap)",
                        "kainate receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ABACAVIR",
            "showDrugName": "ABACAVIR",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                441300
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "nucleoside reverse transcriptase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ABACAVIR",
                    "showDrugName": "ABACAVIR",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to ABACAVIR, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "nucleoside reverse transcriptase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CEFACLOR",
            "showDrugName": "CEFACLOR",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                51039
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "bacterial cell wall synthesis inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CEFACLOR",
                    "showDrugName": "CEFACLOR",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to CEFACLOR, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "bacterial cell wall synthesis inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CEFOXITIN",
            "showDrugName": "CEFOXITIN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                441199
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "bacterial cell wall synthesis inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CEFOXITIN",
                    "showDrugName": "CEFOXITIN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to CEFOXITIN, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "bacterial cell wall synthesis inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CEFTRIAXONE",
            "showDrugName": "CEFTRIAXONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5479530,
                9570985,
                23679441,
                46173365
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "bacterial cell wall synthesis inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CEFTRIAXONE",
                    "showDrugName": "CEFTRIAXONE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to CEFTRIAXONE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "bacterial cell wall synthesis inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CEFUROXIME",
            "showDrugName": "CEFUROXIME",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                2659,
                41375,
                5361202,
                5479529,
                6914282
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "bacterial cell wall synthesis inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CEFUROXIME",
                    "showDrugName": "CEFUROXIME",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to CEFUROXIME, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "bacterial cell wall synthesis inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "EMTRICITABINE",
            "showDrugName": "EMTRICITABINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                60877
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "nucleoside reverse transcriptase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "EMTRICITABINE",
                    "showDrugName": "EMTRICITABINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to EMTRICITABINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "nucleoside reverse transcriptase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ETRAVIRINE",
            "showDrugName": "ETRAVIRINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                193962
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "non-nucleoside reverse transcriptase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ETRAVIRINE",
                    "showDrugName": "ETRAVIRINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to ETRAVIRINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "non-nucleoside reverse transcriptase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LAMIVUDINE",
            "showDrugName": "LAMIVUDINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                60825
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "nucleoside reverse transcriptase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                },
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LAMIVUDINE",
                    "showDrugName": "LAMIVUDINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to LAMIVUDINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC",
                        "PharmGKB"
                    ],
                    "family": [
                        "nucleoside reverse transcriptase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NEVIRAPINE",
            "showDrugName": "NEVIRAPINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                4463
            ],
            "dScore": 0.212,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "non-nucleoside reverse transcriptase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "NEVIRAPINE",
                    "showDrugName": "NEVIRAPINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to NEVIRAPINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "non-nucleoside reverse transcriptase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "EMAPALUMAB-LZSG",
            "showDrugName": "EMAPALUMAB-LZSG",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [],
            "dScore": 0.212,
            "gScore": 0.125,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "UNC13D": "mutated"
                },
                "coherence": {
                    "UNC13D": "UNC13D is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "UNC13D",
                    "entrezId": [
                        201294
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "FDA",
                    "link": "https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling",
                    "name": "FDA"
                }
            ],
            "curatedSource": [
                "FDA"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "EMAPALUMAB-LZSG",
                    "showDrugName": "EMAPALUMAB-LZSG",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in UNC13D are associated with response to EMAPALUMAB-LZSG, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.212,
                    "gScore": 0.125,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "UNC13D",
                            "entrezId": [
                                201294
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "FDA"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CITALOPRAM",
            "showDrugName": "CITALOPRAM",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                2771
            ],
            "dScore": 0.211,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "selective serotonin reuptake inhibitor (SSRI)(Cmap)"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CITALOPRAM",
                    "showDrugName": "CITALOPRAM",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to CITALOPRAM, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.211,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "selective serotonin reuptake inhibitor (SSRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "VENLAFAXINE",
            "showDrugName": "VENLAFAXINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5656
            ],
            "dScore": 0.211,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic inhibitor(Cmap)",
                "norepinephrine reuptake inhibitor(Cmap)",
                "serotoninnorepinephrine reuptake inhibitor (SNRI)(Cmap)"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "VENLAFAXINE",
                    "showDrugName": "VENLAFAXINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to VENLAFAXINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.211,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "adrenergic inhibitor(Cmap)",
                        "norepinephrine reuptake inhibitor(Cmap)",
                        "serotoninnorepinephrine reuptake inhibitor (SNRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PRASUGREL",
            "showDrugName": "PRASUGREL",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                6918456
            ],
            "dScore": 0.211,
            "gScore": 0.4509,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "NTRK1": "mutated"
                },
                "coherence": {
                    "NTRK1": "NTRK1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                }
            ],
            "family": [
                "purinergic receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PRASUGREL",
                    "showDrugName": "PRASUGREL",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in NTRK1 are associated with response to PRASUGREL, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.211,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "purinergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "CANDESARTAN",
            "showDrugName": "CANDESARTAN",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                2541
            ],
            "dScore": 0.211,
            "gScore": 0.3658,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "DOT1L": "mutated"
                },
                "coherence": {
                    "DOT1L": "DOT1L (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "DOT1L",
                    "entrezId": [
                        84444
                    ]
                }
            ],
            "family": [
                "angiotensin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "CANDESARTAN",
                    "showDrugName": "CANDESARTAN",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in DOT1L are associated with response to CANDESARTAN, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.211,
                    "gScore": 0.3658,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "DOT1L",
                            "entrezId": [
                                84444
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "angiotensin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "HYDROCHLOROTHIAZIDE",
            "showDrugName": "HYDROCHLOROTHIAZIDE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                3639
            ],
            "dScore": 0.211,
            "gScore": 0.3658,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "DOT1L": "mutated"
                },
                "coherence": {
                    "DOT1L": "DOT1L (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "DOT1L",
                    "entrezId": [
                        84444
                    ]
                }
            ],
            "family": [
                "thiazide diuretic(Cmap)"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "HYDROCHLOROTHIAZIDE",
                    "showDrugName": "HYDROCHLOROTHIAZIDE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in DOT1L are associated with response to HYDROCHLOROTHIAZIDE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.211,
                    "gScore": 0.3658,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "DOT1L",
                            "entrezId": [
                                84444
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "thiazide diuretic(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "AMIODARONE",
            "showDrugName": "AMIODARONE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                2157
            ],
            "dScore": 0.211,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "potassium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "AMIODARONE",
                    "showDrugName": "AMIODARONE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to AMIODARONE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.211,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "potassium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MORPHINE",
            "showDrugName": "MORPHINE",
            "status": "APPROVED",
            "statusDescription": "Approved",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5288826
            ],
            "dScore": 0.211,
            "gScore": 0.1938,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ABCC3": "mutated"
                },
                "coherence": {
                    "ABCC3": "ABCC3 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "ABCC3",
                    "entrezId": [
                        8714
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "MORPHINE",
                    "showDrugName": "MORPHINE",
                    "target": "marker",
                    "status": "APPROVED",
                    "drugStatusInfo": "Molecular alterations in ABCC3 are associated with response to MORPHINE, a drug approved by FDA",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.211,
                    "gScore": 0.1938,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "ABCC3",
                            "entrezId": [
                                8714
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "REFAMETINIB",
            "showDrugName": "REFAMETINIB",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                44182295
            ],
            "dScore": 0.126,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "MEK inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CC",
                    "link": "http://dgidb.genome.wustl.edu/sources/CancerCommons",
                    "name": "CancerCommons"
                },
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                },
                {
                    "shortName": "MCG",
                    "link": "https://dgidb.genome.wustl.edu/sources/MyCancerGenome",
                    "name": "MyCancerGenome"
                }
            ],
            "curatedSource": [
                "CancerCommons",
                "ChemblInteractions",
                "GuideToPharmacology",
                "JAX-CKB",
                "MyCancerGenome"
            ],
            "cancer": [],
            "indirectGene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "geneDependency": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "REFAMETINIB",
                    "showDrugName": "REFAMETINIB",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "REFAMETINIB is a drug in Clinical Trials that acts as an inhibitor of MAP2K1, a genetic dependency of BRAF gof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "ONC",
                            "geneSymbol": "MAP2K1",
                            "entrezId": [
                                5604
                            ]
                        },
                        "alterations": {
                            "BRAF": "gof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.126,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "CancerCommons",
                        "ChemblInteractions",
                        "GuideToPharmacology",
                        "JAX-CKB",
                        "MyCancerGenome"
                    ],
                    "family": [
                        "MEK inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "REFAMETINIB",
                    "showDrugName": "REFAMETINIB",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to REFAMETINIB, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.022,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "MEK inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "REFAMETINIB",
                    "showDrugName": "REFAMETINIB",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to REFAMETINIB, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.022,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "MEK inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LISURIDE",
            "showDrugName": "LISURIDE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                28864
            ],
            "dScore": 0.12300000000000001,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LISURIDE",
                    "showDrugName": "LISURIDE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "LISURIDE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.12300000000000001,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "LISURIDE",
                    "showDrugName": "LISURIDE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "LISURIDE is a drug in Clinical Trials that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.12300000000000001,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "YOHIMBINE",
            "showDrugName": "YOHIMBINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                8969
            ],
            "dScore": 0.12300000000000001,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "ARID2": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "adrenergic receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "YOHIMBINE",
                    "showDrugName": "YOHIMBINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "YOHIMBINE is a drug in Clinical Trials that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.12300000000000001,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "YOHIMBINE",
                    "showDrugName": "YOHIMBINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "YOHIMBINE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.12200000000000001,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "adrenergic receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MEDICAL CANNABIS",
            "showDrugName": "MEDICAL CANNABIS",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.12200000000000001,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "MEDICAL CANNABIS",
                    "showDrugName": "MEDICAL CANNABIS",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "MEDICAL CANNABIS is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.12200000000000001,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "MEDICAL CANNABIS",
                    "showDrugName": "MEDICAL CANNABIS",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "MEDICAL CANNABIS is a drug in Clinical Trials that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.12200000000000001,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NABIXIMOLS",
            "showDrugName": "NABIXIMOLS",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                9852188,
                44148067
            ],
            "dScore": 0.12200000000000001,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated",
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated",
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                },
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "NABIXIMOLS",
                    "showDrugName": "NABIXIMOLS",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "NABIXIMOLS is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.12200000000000001,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "NABIXIMOLS",
                    "showDrugName": "NABIXIMOLS",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "NABIXIMOLS is a drug in Clinical Trials that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.12200000000000001,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SERTINDOLE",
            "showDrugName": "SERTINDOLE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                60149
            ],
            "dScore": 0.115,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TEND",
                    "link": "https://dgidb.genome.wustl.edu/sources/TEND",
                    "name": "TEND"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "TEND",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "SERTINDOLE",
                    "showDrugName": "SERTINDOLE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "SERTINDOLE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.115,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TEND",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "KETANSERIN",
            "showDrugName": "KETANSERIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3822
            ],
            "dScore": 0.114,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "NCI",
                    "link": "https://dgidb.genome.wustl.edu/sources/NCI",
                    "name": "NCI"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology",
                "NCI"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "KETANSERIN",
                    "showDrugName": "KETANSERIN",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "KETANSERIN is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.114,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "NCI"
                    ],
                    "family": [
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TB-402",
            "showDrugName": "TB-402",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.114,
            "gScore": 0.3833,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "F8": "mutated"
                },
                "coherence": {
                    "F8": "F8 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "F8",
                    "entrezId": [
                        2157
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TB-402",
                    "showDrugName": "TB-402",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "TB-402 is a drug in Clinical Trials that acts as an inhibitor of F8",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.114,
                    "gScore": 0.3833,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "F8",
                            "entrezId": [
                                2157
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RO4987655",
            "showDrugName": "RO4987655",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11548630
            ],
            "dScore": 0.113,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "MEK inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CC",
                    "link": "http://dgidb.genome.wustl.edu/sources/CancerCommons",
                    "name": "CancerCommons"
                },
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "CancerCommons",
                "ChemblInteractions",
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "geneDependency": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "RO4987655",
                    "showDrugName": "RO4987655",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "RO4987655 is a drug in Clinical Trials that acts as an inhibitor of MAP2K1, a genetic dependency of BRAF gof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "ONC",
                            "geneSymbol": "MAP2K1",
                            "entrezId": [
                                5604
                            ]
                        },
                        "alterations": {
                            "BRAF": "gof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "CancerCommons",
                        "ChemblInteractions"
                    ],
                    "family": [
                        "MEK inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "RO4987655",
                    "showDrugName": "RO4987655",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to RO4987655, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "MEK inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "EPLIVANSERIN",
            "showDrugName": "EPLIVANSERIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                121843,
                135456190,
                135515430,
                135979919
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "EPLIVANSERIN",
                    "showDrugName": "EPLIVANSERIN",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "EPLIVANSERIN is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ESMIRTAZAPINE",
            "showDrugName": "ESMIRTAZAPINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                3085218
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ESMIRTAZAPINE",
                    "showDrugName": "ESMIRTAZAPINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "ESMIRTAZAPINE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "NELOTANSERIN",
            "showDrugName": "NELOTANSERIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11683556
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor inverse agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "NELOTANSERIN",
                    "showDrugName": "NELOTANSERIN",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "NELOTANSERIN is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TTD"
                    ],
                    "family": [
                        "serotonin receptor inverse agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PIPAMPERONE",
            "showDrugName": "PIPAMPERONE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                4830
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PIPAMPERONE",
                    "showDrugName": "PIPAMPERONE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "PIPAMPERONE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RITANSERIN",
            "showDrugName": "RITANSERIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5074
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "RITANSERIN",
                    "showDrugName": "RITANSERIN",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "RITANSERIN is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SARPOGRELATE",
            "showDrugName": "SARPOGRELATE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5160
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "SARPOGRELATE",
                    "showDrugName": "SARPOGRELATE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "SARPOGRELATE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TTD"
                    ],
                    "family": [
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SEROTONIN",
            "showDrugName": "SEROTONIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5202
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "growth factor receptor activator(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "SEROTONIN",
                    "showDrugName": "SEROTONIN",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "SEROTONIN is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "growth factor receptor activator(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TEMANOGREL",
            "showDrugName": "TEMANOGREL",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11604525
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TEMANOGREL",
                    "showDrugName": "TEMANOGREL",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "TEMANOGREL is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "DrugBank",
                        "TTD"
                    ],
                    "family": [
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ZOTEPINE",
            "showDrugName": "ZOTEPINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                5736
            ],
            "dScore": 0.113,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)",
                "serotonin receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "DrugBank",
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ZOTEPINE",
                    "showDrugName": "ZOTEPINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "ZOTEPINE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.113,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "GuideToPharmacology",
                        "TTD"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)",
                        "serotonin receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ESMIRTAZAPINE MALEATE",
            "showDrugName": "ESMIRTAZAPINE MALEATE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                6451144
            ],
            "dScore": 0.112,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ESMIRTAZAPINE MALEATE",
                    "showDrugName": "ESMIRTAZAPINE MALEATE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "ESMIRTAZAPINE MALEATE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FLUPENTIXOL",
            "showDrugName": "FLUPENTIXOL",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                17012,
                5281878,
                5281881
            ],
            "dScore": 0.112,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "dopamine receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "FLUPENTIXOL",
                    "showDrugName": "FLUPENTIXOL",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "FLUPENTIXOL is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "dopamine receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "MDMA",
            "showDrugName": "MIDOMAFETAMINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                1615
            ],
            "dScore": 0.112,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "MDMA",
                    "showDrugName": "MIDOMAFETAMINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "MIDOMAFETAMINE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TTD"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PYRIDOXAL",
            "showDrugName": "PYRIDOXAL",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                1050
            ],
            "dScore": 0.112,
            "gScore": 0.3774,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "MOCOS": "mutated"
                },
                "coherence": {
                    "MOCOS": "MOCOS is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "MOCOS",
                    "entrezId": [
                        55034
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "PYRIDOXAL",
                    "showDrugName": "PYRIDOXAL",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "PYRIDOXAL is a drug in Clinical Trials that acts as an inhibitor of MOCOS",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.3774,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "MOCOS",
                            "entrezId": [
                                55034
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "HALOFUGINONE",
            "showDrugName": "HALOFUGINONE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                62894,
                400772,
                456390
            ],
            "dScore": 0.112,
            "gScore": 0.3646,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "COL1A1": "mutated"
                },
                "coherence": {
                    "COL1A1": "COL1A1 (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "COL1A1",
                    "entrezId": [
                        1277
                    ]
                }
            ],
            "family": [
                "collagenase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "HALOFUGINONE",
                    "showDrugName": "HALOFUGINONE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "HALOFUGINONE is a drug in Clinical Trials that acts as an inhibitor of COL1A1",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.3646,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "COL1A1",
                            "entrezId": [
                                1277
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "collagenase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DIHYDROARTEMISININ",
            "showDrugName": "ARTENIMOL",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                107770,
                456410,
                3000518,
                6918483,
                10221470,
                11358077,
                11832956,
                16399850
            ],
            "dScore": 0.112,
            "gScore": 0.3554,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SFPQ": "mutated"
                },
                "coherence": {
                    "SFPQ": "SFPQ is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SFPQ",
                    "entrezId": [
                        6421
                    ]
                }
            ],
            "family": [
                "antimalarial agent(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "DIHYDROARTEMISININ",
                    "showDrugName": "ARTENIMOL",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "ARTENIMOL is a drug in Clinical Trials that acts as an inhibitor of SFPQ",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.3554,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SFPQ",
                            "entrezId": [
                                6421
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "antimalarial agent(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LAPAQUISTAT ACETATE",
            "showDrugName": "LAPAQUISTAT ACETATE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                9874248
            ],
            "dScore": 0.112,
            "gScore": 0.3127,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HMGCR": "mutated"
                },
                "coherence": {
                    "HMGCR": "HMGCR is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HMGCR",
                    "entrezId": [
                        3156
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "LAPAQUISTAT ACETATE",
                    "showDrugName": "LAPAQUISTAT ACETATE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "LAPAQUISTAT ACETATE is a drug in Clinical Trials that acts as an inhibitor of HMGCR",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.3127,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HMGCR",
                            "entrezId": [
                                3156
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RAZUPROTAFIB",
            "showDrugName": "RAZUPROTAFIB",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                46700782
            ],
            "dScore": 0.112,
            "gScore": 0.3059,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTPRB": "mutated"
                },
                "coherence": {
                    "PTPRB": "PTPRB (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTPRB",
                    "entrezId": [
                        5787
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                },
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "RAZUPROTAFIB",
                    "showDrugName": "RAZUPROTAFIB",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "RAZUPROTAFIB is a drug in Clinical Trials that acts as an inhibitor of PTPRB",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.3059,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTPRB",
                            "entrezId": [
                                5787
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank",
                        "TTD"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "HYALURONIC ACID",
            "showDrugName": "HYALURONIC ACID",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.112,
            "gScore": 0.2426,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "VCAN": "mutated"
                },
                "coherence": {
                    "VCAN": "VCAN is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "VCAN",
                    "entrezId": [
                        1462
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "HYALURONIC ACID",
                    "showDrugName": "HYALURONIC ACID",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "HYALURONIC ACID is a drug in Clinical Trials that acts as an inhibitor of VCAN",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.2426,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "VCAN",
                            "entrezId": [
                                1462
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "(+)-AJMALINE",
            "showDrugName": "(+)-AJMALINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                6100671
            ],
            "dScore": 0.112,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "(+)-AJMALINE",
                    "showDrugName": "(+)-AJMALINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "(+)-AJMALINE is a drug in Clinical Trials that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "QUINIDINE BARBITURATE",
            "showDrugName": "QUINIDINE BARBITURATE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                53461739
            ],
            "dScore": 0.112,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "QUINIDINE BARBITURATE",
                    "showDrugName": "QUINIDINE BARBITURATE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "QUINIDINE BARBITURATE is a drug in Clinical Trials that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TETRODOTOXIN",
            "showDrugName": "TETRODOTOXIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                20382,
                443369,
                4490623,
                6324668,
                11174599,
                16759596,
                20055121,
                54592379,
                139251219
            ],
            "dScore": 0.112,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "TETRODOTOXIN",
                    "showDrugName": "TETRODOTOXIN",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "TETRODOTOXIN is a drug in Clinical Trials that acts as an inhibitor of SCN5A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.112,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TTD",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ROLUPERIDONE",
            "showDrugName": "ROLUPERIDONE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                9799284
            ],
            "dScore": 0.111,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ROLUPERIDONE",
                    "showDrugName": "ROLUPERIDONE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "ROLUPERIDONE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.111,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TTD"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ZICRONAPINE",
            "showDrugName": "ZICRONAPINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11465618
            ],
            "dScore": 0.111,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ZICRONAPINE",
                    "showDrugName": "ZICRONAPINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "ZICRONAPINE is a drug in Clinical Trials that acts as an inhibitor of HTR2A",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.111,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TTD"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SPESOLIMAB",
            "showDrugName": "SPESOLIMAB",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.111,
            "gScore": 0.3987,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "IL36RN": "mutated"
                },
                "coherence": {
                    "IL36RN": "IL36RN is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "IL36RN",
                    "entrezId": [
                        26525
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "SAbD",
                    "link": "http://opig.stats.ox.ac.uk/webapps/newsabdab/therasabdab/search/?therapeutic=SPESOLIMAB",
                    "name": "SAbDab"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "SPESOLIMAB",
                    "showDrugName": "SPESOLIMAB",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "SPESOLIMAB is a drug in Clinical Trials that acts as an inhibitor of IL36RN",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.111,
                    "gScore": 0.3987,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "IL36RN",
                            "entrezId": [
                                26525
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "SAbDab"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ELOCTATE",
            "showDrugName": "ELOCTATE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [],
            "dScore": 0.111,
            "gScore": 0.3833,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "F8": "mutated"
                },
                "coherence": {
                    "F8": "F8 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "F8",
                    "entrezId": [
                        2157
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "DIRECT_TARGET",
                    "drug": "ELOCTATE",
                    "showDrugName": "ELOCTATE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "ELOCTATE is a drug in Clinical Trials that acts as an inhibitor of F8",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.111,
                    "gScore": 0.3833,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "F8",
                            "entrezId": [
                                2157
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TTD"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "L-LEUCINE",
            "showDrugName": "LEUCINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                6106
            ],
            "dScore": 0.10200000000000001,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "L-LEUCINE",
                    "showDrugName": "LEUCINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "LEUCINE is a drug in Clinical Trials that acts as an inhibitor of LCMT1, a genetic dependency of BRAF gof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "LCMT1",
                            "entrezId": [
                                51451
                            ]
                        },
                        "alterations": {
                            "BRAF": "gof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.10200000000000001,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "DAPOXETINE",
            "showDrugName": "DAPOXETINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                71353
            ],
            "dScore": 0.10200000000000001,
            "gScore": 0.3925,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "ARID2": "mutated"
                },
                "coherence": {
                    "ARID2": "ARID2 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "family": [
                "selective serotonin reuptake inhibitor (SSRI)(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DB",
                    "link": "https://go.drugbank.com",
                    "name": "DrugBank"
                }
            ],
            "curatedSource": [
                "DrugBank"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": null,
                    "geneSymbol": "ARID2",
                    "entrezId": [
                        196528
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "DAPOXETINE",
                    "showDrugName": "DAPOXETINE",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "DAPOXETINE is a drug in Clinical Trials that acts as an inhibitor of HTR1B, a genetic dependency of ARID2 lof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR1B",
                            "entrezId": [
                                3351
                            ]
                        },
                        "alterations": {
                            "ARID2": "lof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.10200000000000001,
                    "gScore": 0.3925,
                    "gene": [
                        {
                            "driverGene": null,
                            "geneSymbol": "ARID2",
                            "entrezId": [
                                196528
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DrugBank"
                    ],
                    "family": [
                        "selective serotonin reuptake inhibitor (SSRI)(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "SERDEMETAN",
            "showDrugName": "SERDEMETAN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": true,
            "pubchemId": [
                11609586
            ],
            "dScore": 0.101,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "MDM inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "TTD",
                    "link": "http://dgidb.genome.wustl.edu/sources/TTD",
                    "name": "TTD"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "geneDrugInfo": [
                {
                    "interactionType": "GENE_DEPENDENCY",
                    "drug": "SERDEMETAN",
                    "showDrugName": "SERDEMETAN",
                    "target": "target",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "SERDEMETAN is a drug in Clinical Trials that acts as an inhibitor of MDM2, a genetic dependency of BRAF gof",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": {
                        "geneInfo": {
                            "driverGene": "ONC",
                            "geneSymbol": "MDM2",
                            "entrezId": [
                                4193
                            ]
                        },
                        "alterations": {
                            "BRAF": "gof"
                        }
                    },
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.101,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TTD"
                    ],
                    "family": [
                        "MDM inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BMS-754807",
            "showDrugName": "BMS-754807",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                24785538
            ],
            "dScore": 0.022,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "NTRK1": "mutated",
                    "PTEN": "mutated"
                },
                "coherence": {
                    "NTRK1": "NTRK1 is mutated",
                    "PTEN": "PTEN (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "IGF-1 inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "DTC",
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "BMS-754807",
                    "showDrugName": "BMS-754807",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to BMS-754807, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.022,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "IGF-1 inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "BMS-754807",
                    "showDrugName": "BMS-754807",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in NTRK1 are associated with response to BMS-754807, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.022,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "IGF-1 inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "OMIPALISIB",
            "showDrugName": "OMIPALISIB",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                25167777
            ],
            "dScore": 0.022,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated",
                    "BRAF": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated",
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                },
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "PI3K inhibitor(Cmap)",
                "mTOR inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CFB",
                    "link": "http://dgidb.genome.wustl.edu/sources/ClearityFoundationBiomarkers",
                    "name": "ClearityFoundationBiomarkers"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "ClearityFoundationBiomarkers",
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "OMIPALISIB",
                    "showDrugName": "OMIPALISIB",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to OMIPALISIB, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.022,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ClearityFoundationBiomarkers"
                    ],
                    "family": [
                        "PI3K inhibitor(Cmap)",
                        "mTOR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                },
                {
                    "interactionType": "BIOMARKER",
                    "drug": "OMIPALISIB",
                    "showDrugName": "OMIPALISIB",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to OMIPALISIB, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.022,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "PI3K inhibitor(Cmap)",
                        "mTOR inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LY3009120",
            "showDrugName": "LY3009120",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                71721540
            ],
            "dScore": 0.014,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "RAF inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                },
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "GuideToPharmacology",
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LY3009120",
                    "showDrugName": "LY3009120",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to LY3009120, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.014,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "GuideToPharmacology",
                        "JAX-CKB"
                    ],
                    "family": [
                        "RAF inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "IFERANSERIN",
            "showDrugName": "IFERANSERIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                6445539
            ],
            "dScore": 0.013000000000000001,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                },
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "ChemblInteractions",
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "IFERANSERIN",
                    "showDrugName": "IFERANSERIN",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to IFERANSERIN, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.013000000000000001,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions",
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ACALISIB",
            "showDrugName": "ACALISIB",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                11618268
            ],
            "dScore": 0.012,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "PI3K inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ACALISIB",
                    "showDrugName": "ACALISIB",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to ACALISIB, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "PI3K inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "TASELISIB",
            "showDrugName": "TASELISIB",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                51001932
            ],
            "dScore": 0.012,
            "gScore": 0.855,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "PTEN": "mutated"
                },
                "coherence": {
                    "PTEN": "PTEN (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "PTEN",
                    "entrezId": [
                        5728
                    ]
                }
            ],
            "family": [
                "PI3K inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "TASELISIB",
                    "showDrugName": "TASELISIB",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in PTEN are associated with response to TASELISIB, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.855,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "PTEN",
                            "entrezId": [
                                5728
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "PI3K inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "OBATOCLAX",
            "showDrugName": "OBATOCLAX",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                11404337,
                40637217,
                45356963,
                46930997,
                57353643,
                66751253
            ],
            "dScore": 0.012,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "BCL inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "OBATOCLAX",
                    "showDrugName": "OBATOCLAX",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to OBATOCLAX, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "BCL inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PF-04217903",
            "showDrugName": "PF-04217903",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                17754438
            ],
            "dScore": 0.012,
            "gScore": 0.75,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BRAF": "mutated"
                },
                "coherence": {
                    "BRAF": "BRAF (oncogene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "ONC",
                    "geneSymbol": "BRAF",
                    "entrezId": [
                        673
                    ]
                }
            ],
            "family": [
                "c-Met inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "JC",
                    "link": "https://dgidb.genome.wustl.edu/sources/JAX-CKB",
                    "name": "JAX-CKB"
                }
            ],
            "curatedSource": [
                "JAX-CKB"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PF-04217903",
                    "showDrugName": "PF-04217903",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BRAF are associated with response to PF-04217903, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.75,
                    "gene": [
                        {
                            "driverGene": "ONC",
                            "geneSymbol": "BRAF",
                            "entrezId": [
                                673
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "JAX-CKB"
                    ],
                    "family": [
                        "c-Met inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "BIFEPRUNOX",
            "showDrugName": "BIFEPRUNOX",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                208951
            ],
            "dScore": 0.012,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "BIFEPRUNOX",
                    "showDrugName": "BIFEPRUNOX",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to BIFEPRUNOX, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LORCASERIN",
            "showDrugName": "LORCASERIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                11658860
            ],
            "dScore": 0.012,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LORCASERIN",
                    "showDrugName": "LORCASERIN",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to LORCASERIN, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LYSERGIDE",
            "showDrugName": "LYSERGIDE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5761
            ],
            "dScore": 0.012,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LYSERGIDE",
                    "showDrugName": "LYSERGIDE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to LYSERGIDE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "RENZAPRIDE",
            "showDrugName": "RENZAPRIDE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                119574,
                3035241,
                3086547,
                6917985
            ],
            "dScore": 0.012,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "RENZAPRIDE",
                    "showDrugName": "RENZAPRIDE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to RENZAPRIDE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "VABICASERIN HYDROCHLORIDE",
            "showDrugName": "VABICASERIN HYDROCHLORIDE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                11521821
            ],
            "dScore": 0.012,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "VABICASERIN HYDROCHLORIDE",
                    "showDrugName": "VABICASERIN HYDROCHLORIDE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to VABICASERIN HYDROCHLORIDE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "XANOMELINE",
            "showDrugName": "XANOMELINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                60809
            ],
            "dScore": 0.012,
            "gScore": 0.5425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "HTR2A": "mutated"
                },
                "coherence": {
                    "HTR2A": "HTR2A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "HTR2A",
                    "entrezId": [
                        3356
                    ]
                }
            ],
            "family": [
                "acetylcholine receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "XANOMELINE",
                    "showDrugName": "XANOMELINE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in HTR2A are associated with response to XANOMELINE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.5425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "HTR2A",
                            "entrezId": [
                                3356
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "acetylcholine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "APAZIQUONE",
            "showDrugName": "APAZIQUONE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5813717
            ],
            "dScore": 0.012,
            "gScore": 0.4509,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "NTRK1": "mutated"
                },
                "coherence": {
                    "NTRK1": "NTRK1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "NTRK1",
                    "entrezId": [
                        4914
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "NCI",
                    "link": "https://dgidb.genome.wustl.edu/sources/NCI",
                    "name": "NCI"
                }
            ],
            "curatedSource": [
                "NCI"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "APAZIQUONE",
                    "showDrugName": "APAZIQUONE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in NTRK1 are associated with response to APAZIQUONE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.4509,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "NTRK1",
                            "entrezId": [
                                4914
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "NCI"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ELLAGIC ACID",
            "showDrugName": "ELLAGIC ACID",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5281855
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ELLAGIC ACID",
                    "showDrugName": "ELLAGIC ACID",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to ELLAGIC ACID, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FENOLDOPAM HYDROBROMIDE",
            "showDrugName": "FENOLDOPAM HYDROBROMIDE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                11957552
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "dopamine receptor agonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "FENOLDOPAM HYDROBROMIDE",
                    "showDrugName": "FENOLDOPAM HYDROBROMIDE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to FENOLDOPAM HYDROBROMIDE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "dopamine receptor agonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "FLUPIRTINE MALEATE",
            "showDrugName": "FLUPIRTINE MALEATE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                6435335
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "glutamate receptor antagonist(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "FLUPIRTINE MALEATE",
                    "showDrugName": "FLUPIRTINE MALEATE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to FLUPIRTINE MALEATE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "glutamate receptor antagonist(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "HYPERICIN",
            "showDrugName": "HYPERICIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                3663
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "tyrosine kinase inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "HYPERICIN",
                    "showDrugName": "HYPERICIN",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to HYPERICIN, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "tyrosine kinase inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "L-NOREPINEPHRINE",
            "showDrugName": "L-NOREPINEPHRINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                439260
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "L-NOREPINEPHRINE",
                    "showDrugName": "L-NOREPINEPHRINE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to L-NOREPINEPHRINE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "QUERCETIN",
            "showDrugName": "QUERCETIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5280343
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "polar auxin transport inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "QUERCETIN",
                    "showDrugName": "QUERCETIN",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to QUERCETIN, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "polar auxin transport inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "QUERCETIN DIHYDRATE",
            "showDrugName": "QUERCETIN DIHYDRATE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5284452
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "polar auxin transport inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "QUERCETIN DIHYDRATE",
                    "showDrugName": "QUERCETIN DIHYDRATE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to QUERCETIN DIHYDRATE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "polar auxin transport inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "69659-80-9",
            "showDrugName": "TANSHINONE IIA SULFONATE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                125782,
                23669322,
                40580588
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "69659-80-9",
                    "showDrugName": "TANSHINONE IIA SULFONATE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to TANSHINONE IIA SULFONATE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "THIOCTIC ACID",
            "showDrugName": "THIOCTIC ACID",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                864
            ],
            "dScore": 0.012,
            "gScore": 0.3769,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "BLM": "mutated"
                },
                "coherence": {
                    "BLM": "BLM (tumor suppressor gene) is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "TSG",
                    "geneSymbol": "BLM",
                    "entrezId": [
                        641
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "THIOCTIC ACID",
                    "showDrugName": "THIOCTIC ACID",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in BLM are associated with response to THIOCTIC ACID, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3769,
                    "gene": [
                        {
                            "driverGene": "TSG",
                            "geneSymbol": "BLM",
                            "entrezId": [
                                641
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ROXITHROMYCIN",
            "showDrugName": "ROXITHROMYCIN",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5106,
                444037,
                5353933,
                5480431,
                5837004,
                6915744,
                9567573,
                25102720,
                45588114,
                46705420,
                73759751,
                126969152,
                133611834,
                135391136,
                139592915
            ],
            "dScore": 0.012,
            "gScore": 0.3425,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "F2RL1": "mutated"
                },
                "coherence": {
                    "F2RL1": "F2RL1 is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "F2RL1",
                    "entrezId": [
                        2150
                    ]
                }
            ],
            "family": [
                "bacterial 50S ribosomal subunit inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "DTC",
                    "link": "https://dgidb.genome.wustl.edu/sources/DTC",
                    "name": "DTC"
                }
            ],
            "curatedSource": [
                "DTC"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ROXITHROMYCIN",
                    "showDrugName": "ROXITHROMYCIN",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in F2RL1 are associated with response to ROXITHROMYCIN, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.3425,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "F2RL1",
                            "entrezId": [
                                2150
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "DTC"
                    ],
                    "family": [
                        "bacterial 50S ribosomal subunit inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "AZD1305",
            "showDrugName": "AZD1305",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                15605092
            ],
            "dScore": 0.012,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "AZD1305",
                    "showDrugName": "AZD1305",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to AZD1305, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "ELECLAZINE",
            "showDrugName": "ELECLAZINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                71183216
            ],
            "dScore": 0.012,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "late sodium current inhibitor(Cmap)"
            ],
            "source": [
                {
                    "shortName": "GTP",
                    "link": "https://dgidb.genome.wustl.edu/sources/GuideToPharmacology",
                    "name": "GuideToPharmacology"
                }
            ],
            "curatedSource": [
                "GuideToPharmacology"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "ELECLAZINE",
                    "showDrugName": "ELECLAZINE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to ELECLAZINE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "GuideToPharmacology"
                    ],
                    "family": [
                        "late sodium current inhibitor(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "LICARBAZEPINE",
            "showDrugName": "LICARBAZEPINE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                114709
            ],
            "dScore": 0.012,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "voltage-gated sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "TCT",
                    "link": "https://dgidb.genome.wustl.edu/sources/TdgClinicalTrial",
                    "name": "TdgClinicalTrial"
                }
            ],
            "curatedSource": [
                "TdgClinicalTrial"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "LICARBAZEPINE",
                    "showDrugName": "LICARBAZEPINE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to LICARBAZEPINE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "TdgClinicalTrial"
                    ],
                    "family": [
                        "voltage-gated sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "PRIRALFINAMIDE",
            "showDrugName": "PRIRALFINAMIDE",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [
                5745207
            ],
            "dScore": 0.012,
            "gScore": 0.2182,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "SCN5A": "mutated"
                },
                "coherence": {
                    "SCN5A": "SCN5A is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "SCN5A",
                    "entrezId": [
                        6331
                    ]
                }
            ],
            "family": [
                "sodium channel blocker(Cmap)"
            ],
            "source": [
                {
                    "shortName": "CI",
                    "link": "https://dgidb.genome.wustl.edu/sources/ChemblInteractions",
                    "name": "ChemblInteractions"
                }
            ],
            "curatedSource": [
                "ChemblInteractions"
            ],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "PRIRALFINAMIDE",
                    "showDrugName": "PRIRALFINAMIDE",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in SCN5A are associated with response to PRIRALFINAMIDE, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.012,
                    "gScore": 0.2182,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "SCN5A",
                            "entrezId": [
                                6331
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "ChemblInteractions"
                    ],
                    "family": [
                        "sodium channel blocker(Cmap)"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        },
        {
            "standardDrugName": "EMAPALUMAB",
            "showDrugName": "EMAPALUMAB",
            "status": "CLINICAL_TRIALS",
            "statusDescription": "Clinical Trials",
            "therapy": null,
            "target": false,
            "pubchemId": [],
            "dScore": 0.011,
            "gScore": 0.125,
            "pharmCatGermLineAnnotation": "NOT_AVAILABLE",
            "calculatedGeneAnnotations": {
                "cnv": null,
                "expression": null,
                "snv": {
                    "UNC13D": "mutated"
                },
                "coherence": {
                    "UNC13D": "UNC13D is mutated"
                }
            },
            "gene": [
                {
                    "driverGene": "UNCLASSIFIED",
                    "geneSymbol": "UNC13D",
                    "entrezId": [
                        201294
                    ]
                }
            ],
            "family": [
                "Other"
            ],
            "source": [
                {
                    "shortName": "PGKB",
                    "link": "https://dgidb.genome.wustl.edu/sources/PharmGKB",
                    "name": "PharmGKB"
                }
            ],
            "curatedSource": [],
            "cancer": [],
            "indirectGene": [],
            "geneDependency": [],
            "geneDrugInfo": [
                {
                    "interactionType": "BIOMARKER",
                    "drug": "EMAPALUMAB",
                    "showDrugName": "EMAPALUMAB",
                    "target": "marker",
                    "status": "CLINICAL_TRIALS",
                    "drugStatusInfo": "Molecular alterations in UNC13D are associated with response to EMAPALUMAB, a drug in Clinical Trials",
                    "therapy": null,
                    "indirect": null,
                    "geneDependency": null,
                    "sensitivity": "SENSITIVITY",
                    "dScore": 0.011,
                    "gScore": 0.125,
                    "gene": [
                        {
                            "driverGene": "UNCLASSIFIED",
                            "geneSymbol": "UNC13D",
                            "entrezId": [
                                201294
                            ]
                        }
                    ],
                    "cancer": [],
                    "source": [
                        "PharmGKB"
                    ],
                    "family": [
                        "Other"
                    ],
                    "alteration": [],
                    "warning": []
                }
            ]
        }
    ]
}